Sangamo BioSciences, Inc. 
Protocol SB-728-1101 Confidential 
 
Page 1 of 70                                                                                   Version: January 30, 2014 Clinical Study Protocol  
A Phase I, Open-Label Study to Assess the Effect of 
Escalating Doses of Cyclophosphamide on the 
Engraftment of SB-728-T in Aviremic HIV-Infected 
Subjects on HAART  
Protocol Number: SB-728-1101 
BB-IND: 14129 
Sponsor: Sangamo BioSciences, Inc. 
Point Richmond Tech Center II 501 Canal Blvd., Suite A100 Richmond, CA  94804 Phone:  (510) 970-6000 Fax:  (510) 970-6009 
Medical Monitor: 
 Winson Tang, M.D.  
Phone:  (510) 970-7800 Fax:  (510) 970-6009 
Original Version: 
Amendment 1: Amendment 2:  Amendment 3: Amendment 4: Amendment 5: Amendment 6: Amendment 7: Amendment 8: Amendment 9:  November 15, 2011 March 14, 2012 August 3, 2012  November 9, 2012 April 18, 2013 June 21, 2013 August 22, 2013 October 04, 2013 November 18, 2013 January 30, 2014   
Confidentiality Statement 
This document contains confidential information. It is intended solely for the use of the principal 
investigator, co-investigators, staff, appropriate in stitutional review boards or ethical committees, and 
other required regulatory bodies.
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 3 of 70                                                                                   Version: January 30, 2014 TABLE OF CONTENTS 
1.     IN TRODUCT ION ................................................................................................... 11 
1.1 CLINICAL EXPERIENCE WITH SB-728-T ............................................................... 11 
1.2 CYCLOPHOSPHAMIDE TO ENHANCE SB-728-T  ENGRAFTMENT  .............................. 12 
1.2.1 Cyclophosphamide and Adaptive Immunotherapy  ............................................. 13 
1.2.2 Safety of Cyclophosphamide in Autoimmune Disease  ....................................... 13 
1.2.3 Use of Cyclophosphamide in HIV  ................................................................... 14 
1.3 HAART  TREATMENT INTERRUPTION  ................................................................... 14 
1.4 RISK BENEFIT ANALYSIS  .................................................................................... 15 
1.5 STUDY HYPOTHESIS  .......................................................................................... 16 
2.  STUDY OBJE CTIVES ........................................................................................ 16 
2.1 PRIMARY OBJECTIVE  ......................................................................................... 16 
2.2 SECONDARY OBJECTIVES  .................................................................................. 16 
3.  STUDY DESIGN ................................................................................................. 16 
3.1 OVERVIEW  ........................................................................................................ 17 
3.2 NUMBER OF SUBJECTS  ...................................................................................... 17 
3.3 DOSE ESCALATION  ............................................................................................ 17 
3.4 COHORT EXPANSION  ......................................................................................... 17 
3.5 STUDY DURATION  .............................................................................................. 17 
3.6 VISIT SCHEDULE  ............................................................................................... 17 
3.7 STUDY PROCEDURES  ........................................................................................ 18 
4.  SUBJECT SEL ECTION ..................................................................................... 18 
4.1 INCLUSION CRITERIA  .......................................................................................... 18 
4.2 EXCLUSION CRITERIA  ........................................................................................ 19 
5.  INFORMED CONSENT ...................................................................................... 20 
6.  STUDY METHODOLOGY .................................................................................. 20 
6.1 SCREENING VISIT PROCEDURES  ......................................................................... 20 
6.2 SUBJECT ENROLLMENT PROCEDURES ................................................................. 21 
6.3 PRE- LEUKAPHERESIS AND LEUKAPHERESIS  ........................................................ 21 
6.3.1 Pre-Leukapheresis:  ......................................................................................... 21 
6.3.2 Leukapheresis:  ............................................................................................... 21 
6.4 BASELINE ASSESSMENTS  ................................................................................... 22 
6.4.1  Baseline for Research Blood Collection:  ....................................................... 22 
6.4.2 Baseline:  ....................................................................................................... 22 
6.5 STUDY TREATMENT AND FOLLOW -UP .................................................................. 22 
6.5.1  Cyclophosphamide Administration  ............................................................... 22 
6.5.2 Day 0 – SB-728-T infusion ............................................................................. 24 
6.5.3 Day 1 ............................................................................................................ 24 
6.5.4 Day 5 (- 1 day) (Cohorts 4 and 5 only)  ............................................................. 24 
6.5.5 Week 1, Day 12 (-1 day) (Cohorts 4 and 5 only), Week 2, Week 3, and Week 4 (+/- 
2 day)  24 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 4 of 70                                                                                   Version: January 30, 2014 6.5.6 Weeks 6, 8, 10, 12, 14, 18 and 22: 16-Week HAART Treatment Interruption  ....... 25 
6.5.7 Month 7, Month 8, Month 10, Month 12 (+/- 1 week)  ........................................ 26 
6.5.8 Long-Term Follow-up  .................................................................................... 27 
7.  INSTRUCTIONS FOR EVALUATIO NS ............................................................. 27 
8.  MEDICATIONS .................................................................................................. 28 
8.1 SB-728-T ........................................................................................................ 28 
8.1.1  Inventory, Storage, and Handling of the Drug Product  ...................................... 28 
8.1.2 SB-728-T Administration  ............................................................................... 29 
8.1.3 Precautions  .................................................................................................... 29 
8.1.4 Dose Modifications  ........................................................................................ 30 
8.2 CYCLOPHOSPHAMIDE  ......................................................................................... 30 
8.3 HAART ............................................................................................................ 31 
8.3.1 Discontinuation of HAART  ............................................................................ 31 
8.3.2 Reinstitution of HAART  ................................................................................. 31 
8.4 CONCOMITANT MEDICATION  ............................................................................... 31 
9.  SAFETY AND POTE NTIAL RI SKS ................................................................... 32 
9.1 SB-728-T ........................................................................................................ 32 
9.1.1 Emergence of CXCR4 HIV  ............................................................................. 32 
9.1.2 Carcinogenicity  ............................................................................................. 32 
9.1.3 Replication Competent Adenovirus (RCA)  ....................................................... 33 
9.1.4 Immunogenicity  ............................................................................................. 33 
9.2 CYCLOPHOSPHAMIDE  ......................................................................................... 34 
9.3 HAART  TREATMENT INTERRUPTION (TI) ............................................................. 34 
10. ADVERSE EVENTS ........................................................................................... 36 
10.1 ADVERSE EVENT REPORTING PERIOD  ................................................................. 36 
10.2 DEFINITIONS OF AN ADVERSE EVENT  .................................................................. 36 
10.3 RECORDING OF AN ADVERSE EVENT  ................................................................... 37 
11. SERIOUS ADVERSE  EVENT ............................................................................ 38 
11.1 SERIOUS ADVERSE EVENT REPORTING PERIOD  ................................................... 38 
11.2 DEFINITIONS OF A SERIOUS ADVERSE EVENT  ...................................................... 38 
11.3 RECORDING OF A SERIOUS ADVERSE EVENT  ....................................................... 39 
12. SUBJECT WITHDRAWAL, DOSE ESCALATION, AND STOPPING RULES .. 39 
12.1 SUBJECT WITHDRAWAL AND DISCONTINUATION FROM STUDY  ............................... 39 
12.2 DOSE ESCALATION RULES ................................................................................. 39 
12.3 COHORT EXPANSION  ......................................................................................... 40 
12.4 STOPPING RULES .............................................................................................. 40 
12.4.1 Stopping Rules for Treatment Interruption  .................................................... 40 
12.4.2 Stopping Rules for Study  ............................................................................ 40 
13. STATISTICAL ANALYSIS AND DATA ANA LYSIS .......................................... 41 
13.1 SAMPLE SIZE .................................................................................................... 41 
13.2 STATISTICAL METHODS /DATA ANALYSIS  .............................................................. 42 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 5 of 70                                                                                   Version: January 30, 2014 13.3 INTENT -TO-TREAT POPULATION  .......................................................................... 42 
13.4 DEMOGRAPHICS  ................................................................................................ 42 
13.5 ENDPOINTS AND ANALYSIS  ................................................................................. 42 
13.5.1 Primary Endpoint  ....................................................................................... 42 
13.5.2 Secondary Endpoints  .................................................................................. 43 
14. INVESTIGATOR OB LIGATIONS ....................................................................... 43 
14.1 INFORMED CONSENT  ......................................................................................... 43 
14.2 INSTITUTIONAL REVIEW BOARD AND BIOSAFETY COMMITTEE  ................................ 44 
14.2.1. Protocol Amendments  ................................................................................. 44 
14.2.2. Other Reporting Obligations  ........................................................................ 44 
14.3 SUBJECT PRIVACY  ............................................................................................. 44 
14.4 REPORTING OBLIGATIONS  .................................................................................. 44 
15. ADMINISTRATIVE CO NSIDERAT IONS ............................................................ 44 
15.1 STUDY DOCUMENTATION  ................................................................................... 44 
15.2 RECORD RETENTION  ......................................................................................... 45 
15.3 CASE REPORT FORMS  ....................................................................................... 45 
15.4 TERMINATION OF THE STUDY  .............................................................................. 45 
15.5 STUDY MONITORING  .......................................................................................... 46 
15.6 PUBLICATION STATEMENT  .................................................................................. 46 
15.7 STUDY FUNDING  ................................................................................................ 47 
REFERENC ES .............................................................................................................. 48 
APPENDIX 1:  SCHE DULE OF EVENTS ..................................................................... 50 
APPENDIX II: DIVISION OF AIDS T ABLE FOR GRADING THE SEVERITY OF 
ADULT AND PEDIATRIC ADVERSE E VENTS ................................................. 51 
 
  
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 6 of 70                                                                                   Version: January 30, 2014 Protocol SB-728-1101 Synopsis 
Title A  Phase I, Open-Label Study to Assess the Effect of Escalating Doses of 
Cyclophosphamide on the Engraftment of  SB-728-T in Aviremic HIV-Infected Subjects on HAART  
Sponsor Sangamo BioSciences, Inc. 
Investigational Products SB-728-T (Autologous CD4+ T-cells gene tically modified at the CCR5 gene 
by Zinc Finger Nucleases SB-728). 
Objectives Primary:  
To evaluate the safety and tole rability of escalating doses of 
cyclophosphamide administered up to 3 days prior to SB-728-T infusion. 
Secondary:  
1. Evaluate the effect of escalating doses of cyclophosphamide on SB-728-T 
engraftment 
2. Evaluate the effect of SB-728-T on  plasma HIV-1 RNA levels following 
HAART interruption 
3. Evaluate long-term persistence of SB-728-T in peripheral blood as 
measured by pentamer PCR 
4. Evaluate change in CD4+ T-cell count s in peripheral blood after treatment 
with SB-728-T 
5. Evaluate the change in HIV reservoirs  as part of exploratory research 
Study Population Up to 40 aviremic HIV-infected s ubjects on stable HAART may be enrolled 
and treated in 5 dose cohorts.  
Main Inclusion 
Criteria HIV diagnosed  men and women >  18 years of age on HAART with 
undetectable viral loads for the preced ing 3 months and peripheral blood 
CD4+ T-cell counts > 500 cells/µL at screening. 
Study Design Phase 1, open-label, dose escalation, multi-center study. 
Treatment Plan Up to 40 subjects will be enrolled and treated in one of five treatment cohorts: 
Cohort 1: Intravenous cyclophosphamide 200 mg 
Cohort 2: Intravenous cyclophosphamide 0.5 g/m2 
Cohort 3: Intravenous cyclophosphamide 1.0 g/m2 
Cohort 4: Intravenous cyclophosphamide 2.0 g/m2 
Cohort 5: Intravenous cyclophosphamide 1.5 g/m2 
 
Within each cohort, treatment will be staggered so that each subsequent 
subject cannot be infused with cyclophosphamide until at least 2 weeks after 
the preceding subject. Up to 3 da ys after receiving cyclophosphamide, 
subjects will be infused with 0.5 to 4.0 x 1010 SB-728-T cells. A Safety 
Monitoring Committee will determine if it is safe to dose escalate prior to treatment of subsequent cohorts.    If one subject within a cohort develops  a dose limiting toxicity (DLT) defined 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 7 of 70                                                                                   Version: January 30, 2014 as a Grade 3 non-hematological adverse event (AE) excluding alopecia or 
Grade 4 hematological AE related to  cyclophosphamide, 3 additional subjects 
will be enrolled and treated in that cohort.   If no DLT develops in 3 s ubjects in Cohort 5 (1.5 g/m
2), additional subjects 
may be enrolled into that cohort.   Upon evaluation of data from Cohort 5 (1.5 g/m
2), the sponsor may elect to 
enroll  additional subjects into  Cohort 3 (1.0 g/m2). 
 Subjects with aviremia and CD4 cell counts ≥500 cells/µL will have their anti-
retroviral treatment stop ped 6 weeks after SB-728-T  infusion. HAART will be 
discontinued for a period of at least 16 weeks.  
During the 16-week treatment interrup tion, HAART will be reinstituted in 
subjects whose CD4 cell counts drop to  <500 cells/µL an d/or whose HIV-
RNA increases to >100,000 copies/mL on three consecutive measurements 
tested every 2 weeks. 
At the end of the 16-week treatment interruption:  
• HAART will be reinstituted in subjects with HIV RNA levels >10,000 
copies/mL and/or CD4 <500 cells/µL.  
• Subjects with HIV RNA levels ≤10,000 copies/mL and CD4 count ≥ 
500 cells/µL may elect to remain  off HAART and undergo extended 
TI (subjects with HIV RNA levels below limit of detection will remain 
off HAART).  
During extended TI, HAART will be reinstit uted in subjects when one or both 
of the following criteria are met:  
• HIV RNA levels > 10,000 copies/mL, confirmed by two additional consecutive monthly measurements 
• CD4 count < 500 cells/µL, confirmed by an additional consecutive monthly measurement  
 
 
Study Duration The duration of study participation will be approximately 15 months for each 
subject divided into approximately 3 m onths for screening,  leukapheresis, and 
SB-728-T production, and 12 months for treatment and study follow-up.   
Sample Size and Analyses This is a phase 1 study in which three to  six evaluable subjects in each cohort 
will be treated to evaluate safety of each cyclophosphamide dose level. A cohort can be expanded if there is no D LT in the first 3 subjects treated or no 
more than 1 DLT in 6 subject s treated in that cohort. The primary focus of this 
study is to evaluate the safety of  escalating doses of cyclophosphamide 
administered prior to the SB-728-T infusion.  As such, if no adverse events are 
observed in a group of three evaluable s ubjects, we can be 95% confident that 
the true adverse event rate is less th an 70%. Expansion of each cohort to 6 
subjects will decrease the rate to 46%.Th ere will be limited statistical power to 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 8 of 70                                                                                   Version: January 30, 2014  
  evaluate efficacy and related biological endpoints. Therefore, analyses will be primarily descriptive and e xploratory in nature.   
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 9 of 70                                                                                   Version: January 30, 2014  
Schema of the Study Visits   
 
 
releaseScreenA
p
h
e
r
e
s
i
sSB‐728‐T 
Production  
6‐8 weeksInfusion and Safety Evaluations ‐12 months
BL CTX D0   D1    1    2    3    4    6    8    10    12    14    18    22        7    8   10   12
Week  MonthCTX1,2SB‐728‐T INFUSION
Treatment InterruptionL
o
n
g
T
e
r
m
F
o
l
l
o
w
U
pD5D12BL  
BR
1Cohort 1: IV cyclophosphamide  200 mg 
Cohort 2: IV cyclophosphamide  0.5 g/m2 
Cohort 3: IV cyclophosphamide  1.0 g/m2 
Cohort 4: IV cyclophosphamide  2.0 g/m2 
Cohort 5: IV cyclophosphamide  1.5 g/m2  
 
2 Administer CTX up to 3 days prior to Day 0. 
Enrollment  of cohorts will be sequential.  
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 10 of 70                                                                                   Version: January 30, 2014 ABBREVIATIONS 
AE  adverse event/experience 
AIDS  acquired imm unodeficiency syndrome 
ALP  alkaline phosphatase ALT  alanine aminotransferase (SGPT) ANC  absolute neutrophil count   AST  aspartate aminotransferase (SGOT) CBC  complete blood count CCR2  chemokine (C-C motif) receptor 2 CCR5  chemokine (C-C motif) receptor 5 CD4  cluster of differentiation 4 C of A  Certificate of Analysis CRF  case report form CTX  cyclophosphamide CXCR4 chemokine (C-X -C motif) receptor 4 
DLT  dose limiting toxicity DMSO  dimethyl sulfoxide  DNA  deoxyribonucleic acid ELISA  enzyme linked immunoassay FDA  Food and Drug Administration HAART highly active antiretroviral therapy HBsAg hepatitis B surface antigen HCV  hepatitis C virus HIV  human immunodeficiency virus IFN  interferon INR  immunologic nonresponders 
IR  immunologic responders 
IV  intravenous IRB  institutional review board NCI  National Cancer Institute NNRTI  non-nucleoside reverse transcriptase inhibitors  
NRTI  nucleoside reverse transcriptase inhibitors 
NIH  National Institutes of Health PBMC  peripheral blood mononuclear cell PCR  polymerase chain reaction PI  Principal Investigator RCA  replication-competent adenovirus RNA  ribonucleic acid RNAi  RNA interference  SAE  serious adverse event SB-728-T SB-728 modified CD4+ T-cells SMC  Safety Monitoring Committee TI  Treatment Interruption TIL  tumor infiltrating lymphocytes VL  viral load ZFN  zinc finger nucleases 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 11 of 70                                                                                   Version: January 30, 2014 1.     INTRODUCTION 
The advent of potent anti-retrovi ral agents has changed HIV inf ection from a nearly universal 
fatal disease to a chronic viral infection. However,  in response to selection pressures associated 
with the use of antiretrovirals, the virus is developing resistance to many of these drugs. Thus, 
there is a need for new therapeutic approach es that can eradicate HIV such as T-cell 
immunotherapy. The objectives of this therapy are to augment HIV-specific T-cells and to 
reverse or decrease the progressi ve destruction of CD4+ T-cells that leads to clinical AIDS. 
However, these CD4+ T-cells remain susceptible to infection with HIV. Sangamo BioSciences, 
Inc. (Sangamo) has developed a process to modify autologous CD4+ T-cells ex vivo  at the CCR5 
gene by zinc finger nucleases (ZFN) encoded by  SB-728 in a replicatio n deficient adenoviral 
vector. Since CCR5 is an importa nt co-receptor for HIV entry, it is hypothesi zed that disruption 
of CCR5 in CD4+ T-cells with zinc finger nucl eases will offer a survival advantage to these 
cells.  
SB-728-T is the name of the experimental agent th at has been administered to subjects infected 
with HIV. SB-728-T consists of autologous enrich ed CD4+ T-cells that have been transduced ex 
vivo with SB-728 resulting in modification of the CCR5 gene. SB-728 is a replication deficient 
recombinant Ad5/35 viral vector encoding th e CCR5 specific ZFNs (SBS8196z and SBS8267) 
which through transient episomal expression delivers these nucleases to transduced cells. The 
two ZFNs bind to a composite 24-bp sequence fo und specifically in the re gion encoding the first 
transmembrane domain of the CCR5 gene, just upstream from the naturally occurring CCR5 delta 32 mutation. Expression of the CCR5-specifi c ZFNs induces a double stranded break which 
is repaired by the cell leading to random sequence insertions or deletions in ~30% of cells 
transduced with SB-728. These insertions and deletions di srupt the CCR5 coding sequence 
leading to frameshift mutation and termination of CCR5 protein expression. Additional human 
pre-clinical information can be found in the Clinical Investigator’s Brochure for SB-728-T. 
1.1 Clinical Experience with SB-728-T  
SB-728-T has been administered to over 60 subject s in three ongoing Phase 1 studies to date, one 
sponsored by the University of Pennsylvania (protocol number 806383) and the other two by 
Sangam
o (SB-728-0902 and SB-728-1002). SB-728-0902 and the PENN study have enrolled a 
total of 21 aviremic subjects on HAART to date ; 6 immunologic responde rs (IR) with CD4 > 450 
cells/µL and 15 immunologic nonre sponders (INR) with CD4 < 500 cells/uL. Subjects were 
infused with 5 to 30 billion cells. The mean  CD4 and SB-728-T count increased by 1533/µL 
(range 216-3025) and 83/µL, respectively, on day 7 in IR and by 820/uL (range 133-4467) and 
19/µL, respectively, in IN R from the 2 studies. Increases in  CD4 over time correlated with SB-
728-T engraftment ( г=0.78, p<0.0001). SB-728-T was detected in the gut mucosa of all 18 
subjects biopsied (median 6%).  
A HAART treatment interrupti on (TI) was performed 4 weeks after SB-728-T infusion (5-10 
billion cells) in the 6 IRs. HIV-RNA dropped ~0.8- 2.1 log from their peak levels in 3 of the 6 
subjects ( Figure 1.1-1 ). In one CCR5 delta 32 heterozygous  subject with a viral setpoint of 
165,000 copies/mL, viral load (VL) peaked at 6247 copies/mL during Week 6 of TI and was 
undetectable by Week 12. Similarly, a subj ect in Sangamo Study SB-728-0902 had a >1-log 
decrease in his HIV-RNA when he underwent a TI  one year after the infusion of 10 billion SB-
728-T cells. Furthermore, in SB-728-0902, PBMC HIV proviral DNA was evaluated using a new 
Digital Droplet qPCR method. Samples with previ ously undetectable leve ls using traditional 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 12 of 70                                                                                   Version: January 30, 2014 qPCR now showed measurable proviral DNA. Thr ee of the six subjects with >11 month follow-
up had an ~1-log decrease over time.  
 
Figure 1.1-1: Viral Load Following Treatment Interruption in Immunologic Responders 
 
 
The results to date suggest SB-728-T infusion increases CD4 counts that persist over time. SB-
728-T expands rapidly and home to the gut. Pr eliminary data suggest that SB-728-T may 
decrease proviral DNA. In one subject with th e highest level of CCR5 modification, VL was 
controlled (< limit of detection) without HAART . There have been no serious adverse events 
(SAEs), associated with SB-728-T, reported to da te. SB-728-T infusions were well tolerated with 
only mild reversible infusion related adverse even ts (AEs). The most common AEs were a garlic 
odor caused by the DMSO required for cel l freezing, and fever and chills.  
1.2 Cyclophosphamide to E nhance SB-728-T Engraftment 
Cyclophospham
ide is a nitrogen mustard alkylati ng agent that attaches an alkyl group to the 
guanine base of DNA. It is a prodrug that is converted by mixed function oxidase enzymes in the 
liver to the main active meta bolite, phosphoramide mustard whic h forms DNA crosslink between 
and within DNA strands. The unchanged drug has a ha lf-life of 3 to 12 hrs and is eliminated 
primarily in the form of metabolites although 5 to  25% of the drug is excreted unchanged in the 
urine. 
Preclinical studies have shown that cyclophosphamide can deplet e T-cells and macrophages with 
rapid repopulation of lymphoid tissues upon discontinuation of the drug. Normal numbers of 
different T-cell populations were fully restored in mice 16 to 30 days after a single dose of cyclophosphamide ( Kolb, Poupon et al. 1977). In another study, the total lym
 phocyte count in 
mice nadired at <10% of normal in the thymus, bone marrow, spleen and lymph nodes three days Days0 14 28 42 56 70 84 98 112 126 140 154 168 182Viral load (Copies/mL)
101102103104105106
Viral Setpoint (Copies/mL)
101102103104105106
Subjects
201
203
204
205 *
251
253Treatment Interruption
*CCR5 - Δ32 Heterozygote
Dotted line denotes reinstitution of HAART
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 13 of 70                                                                                   Version: January 30, 2014 after a single injection of cyclophosphamide (300mg/kg). The repopulation kinetics differed 
markedly within these tissues with the thymus reaching normal numbers by day 14 and twice 
normal by day 21. The bone marrow and spleen were normal by day 7 and 11, respectively but the lymph nodes were only at 30% of normal by day 21 (Willers and Sluis, 1975). These data demonstrate that the lymphodepleting effects of  cyclophosphamide are readily reversible with 
rapid repopulation of lymphoid organs  when the drug is discontinued.   
1.2.1 Cyclophosphamide and Adaptive Immunotherapy 
Cyclophospham
ide has been shown to have benefi cial immunomodulatory effects that may be 
exploited for adaptive immunotherapy. Several mech anisms have been suggested including 1) T-
cell growth factors such as type 1 IFN, 2) de ndritic cell expansion and activation with antigen 
driven T cell proliferation, 3) improved homing to lymphoid organs, 4) homeostatic proliferation 
and 5) elimination of regulatory T-cells.  
Lymphodepletive treatment to enhance engraftmen t of adoptively transferred T-cells has been 
pioneered in the use of autologous  T-cells in the treatment of can cer. The T cell populations used 
in these studies consisted of antigen specific or  chimeric T cell receptor -transduced autologous 
cells. Recently there has been significant clinical success with this approach, with 
lymphodepletion an important contributing factor . Dudley and Rosenber g at the NCI treated 
melanoma subjects with cyclophosphamide and fluda rabine prior to adop tive cell transfer of 
expanded tumor infiltrating lymphoc ytes and showed a 51% objective  clinical response rate of 
tumor shrinkage (Dudley et al., 2005; Dudley  and Rosenberg, 2003). More recently, the 
beneficial effect of a non-myeloablative ly mphodepleting regimen on adoptive T-cell therapy 
was demonstrated in chronic lymphocytic leukemi a patients treated with low doses of chimeric 
antigen receptor CD19 (C ART19) transduced autologous T-cel ls (Porter et al., 2011). These 
results demonstrate that nonmyeloablative lymphode pletion prior to adoptiv e transfer of T-cells 
results in greatly enhanced in vivo expansion.  Furthermore, the expanded cells retain their 
immunologic function.      
1.2.2 Safety of Cyclophosphamide in Autoimmune Disease 
Cyclophospham
ide has been successfully depl oyed as therapy for numerous autoimmune 
diseases including  Goodpasture's syndrome, systemic lupus erythematous, rheumatoid arthritis, 
Wegener's granulomatosis, and membranous glom erulonephritis. Adverse effects and toxicities, 
including hemorrhagic cystitis  and gonadal dysfunction are dos e dependent and are uncommon 
with total cumulative doses below 10 g. The risk of malignancy w ith oral therap y is proportional 
to the cumulative dose and increases substant ially at cumulative dose s greater than 30 g. 
Treatment with cumulative doses of 10 g or less has been shown to be associated with incidence 
of malignancy similar to that of a control population (Baker et  al., 1987). Importantly, unlike 
other cytoreductive agents, cyclophosphamide has no cumulative bone marrow toxicity. 
Table 1.2.2-1  is reproduced from a paper detaili ng the side-effects of cyclophosphamide in 
subjects with autoimmune disease (Martin et al , 1997). A total of 329 subjects with a variety of 
autoimmune diseases received intravenous (IV) cyclophosphamide in nine studies. The mean 
cumulative dose ranged from 1.4 g to 16 g. Infecti on was the most common side effect but most 
of the subjects were also rece iving glucocorticoid. Hemorrhagic cy stitis was seen in  only 2 of the 
studies and may be prevented by adequate fluid intake to induce a diruesis. Only two of the 
studies reported cancer and the total was seven subjects. The cumulative dose of 
cyclophosphamide that was administered in these two studies was 4.7 and 10 grams. 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 14 of 70                                                                                   Version: January 30, 2014  
Table 1.2.2-1: Literature Review of the Side Effects of Intravenous Cyclophosphamide 
Pulse Therapy in Subjects with Autoimmune Disease 
 
1.2.3 Use of Cyclophosphamide in HIV 
The effect of cyclophospham
ide on HIV cellular reservoir in subjects receiving HAART was 
evaluated in Clinical Study ACTG 380 (Bartlett et al., 2002). Ten treatm ent naïve HIV subjects 
were treated with stavudine, lamivudine and nelf inavir. When the subjects became aviremic on 
two serial tests, they were randomized  equally to HAART al one or HAART plus 
cyclophosphamide. Cyclophosphamide was administer ed every 6 weeks at three escalating dose 
levels (750 mg/m2, 1.2 g/m2 and 1.8 g/m2, or a cumulative dose of 3.75 g/m2 over 12 weeks). 
Total lymphocyte counts decreas ed by a mean of 709 cells/mm3 (p<0.02 compared with control 
patients), and CD4 counts were not significantly  affected. HIV proviral DNA decreased similarly 
in both groups but HIV RNA increased in th e cyclophosphamide group, an observation that was 
attributed to non-compliance with HAART. The study demonstrated that the use of 
cyclophosphamide was lymphodepleting, did not significantly reduce total CD4 counts, and was 
adequately tolerated. Toxicity included transien t nausea following the infusion; one subject with 
Grade 3 neutropenia and one subject with Grade 2 thrombocytopenia. Additional information on the safety of cyclophosphamide is discussed in Section 9.2.  
1.3 HAART Treatment Interruption 
HAART TI was initially advocated  to enhance antiviral immune response in acute HIV infection 
(Paton, 200
8) and in the setting of virologic fa ilure and multidrug resistance (Lawrence et al., 
2003). However, studies conducted to date have failed to demonstrate a clinical bene fit in either 
setting. In subjects with successfully  treated chronic HIV infection, TI  is associated with inferior 
clinical outcomes (Oxenius et  al, 2002). However, TI has been successfully deployed as an 
analytical method to assess the effectiveness of different imm unologic/immune-modulatory 
interventions, especially during vaccine tr ials. The kinetics of viral rebound are well 
characterized, typically occurri ng within 2 to 4 weeks follow ing discontinuation of drug, and 
viral replication is routinely re-suppressed with resumption of therapy. Data from the currently 
ongoing U Penn study suggest that TI  can be safely performed in  the currently proposed study 
(Section 9.3 ). 

Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 15 of 70                                                                                   Version: January 30, 2014 A variety of in-vitro  studies may be used to assess HIV- 1 specific immune responses following 
the infusion of CCR5 disrupted CD4 cells. However, the correlation of in vitro  testing to immune 
protection in vivo  is largely unknown (van Lunzen et  al, 2007). By comparison, plasma HIV 
RNA level is an excellent biomarker for assessing th e antiviral activity of a test agent in patients 
with chronic HIV infection. Therefore, sustai ned suppression of plasma HIV-1 RNA after the 
discontinuation of HAART and or  the protection of CD4 cell lo ss associated with ongoing viral 
replication would be the most stringent test of an immunologic intervention such as SB-728-T. 
In the current study, only subjects with aviremia and CD4 cell counts ≥ 500 cells/µL at the 
initiation of the TI will have HAAR T interrupted. In addition, subjec ts will be monitored closely 
during the TI period and HAART will be reinstitut ed in subjects in whom CD4 cell counts drop 
to <500 cells/µL and/or whose HIV-RNA incr eases to >100,000 copies/mL over a sustained 
period (defined as three consecutive measurements tested every 2 weeks). 
At the end of the 16-week TI: 
• HAART will be reinstituted  in subjects with HIV RNA levels >10,000 copies/mL 
and/or CD4 <500 cells/µL.   
• Subjects with HIV RNA levels ≤  10,000 copies/mL and CD4 count ≥ 500 cells/µL 
may elect to remain off HAART and under go extended TI (subjects with HIV RNA 
levels below the limit of detection will remain off HAART).  
 
During extended TI, HAART will be reinstituted in  subjects when one or both of the following 
criteria are met: 
• HIV RNA levels > 10,000 copies/mL, confirmed by two additional consecutive 
monthly measurements. 
• CD4 count < 500 cells/µL, confirmed by an additional consecutive monthly 
measurement. 
Subjects may have HAART reinstituted at any time at the discretion of th e subject and/or PI.  
1.4 Risk Benefit Analysis 
Following myeloablative conditioni ng regim
ens for hematopoietic stem cell transplants, T cell 
proliferation and immunoglobulin production are usually impaired for 6 to 12 months post 
transplant but may persist for as long as 4 to 10 years after autologous stem cell transplantation 
(Nordoy T et al., 2001). Adoptive T- cell therapy has been successfully  applied to the rescue of 
chemotherapy induced lymphopenia in the setti ng of non-Hodgkin’s lymphoma (Laport et al, 
2003), chronic myelogenous leukemia (Rapoport et al , 2004), relapsed acute leukemia (Porter et 
al, 2006) and refractory multiple myeloma by Dr. Carl June and his colleagues at UPENN.  
The kinetics of immune reconstitution with au tologous polyclonal CD3/CD28 stimulated T-cells 
(~1x1010 cells) following high dose chemotherapy with busulfan and autologous stem cell 
transplantation in multiple myeloma was evaluated in three successive trials. In the first study, 52 
subjects were randomized to receive a single in fusion of CD3/CD28 stimula ted T- cells, either 
12 or 100 days after stem cell transplantation (Rapoport et al., 2005). T-cells were infused two 
days after stem cell infusion in the subsequent study (Rapoport et al., 2011 and Stadtmauer et al., 
2011). There was a rapid reconstitution of lymphocyt es with normal circulat ing levels achieved 
by day 5. A lymphocytosis was observed in ~30% of the patients that persisted for up to 8 weeks. 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 16 of 70                                                                                   Version: January 30, 2014 Reconstitution of T cell to normal levels oc curs by 5 days post T-cell infusion but the 
lymphocyte count was higher in subjects that re ceived T-cells on day 2 relative to those who 
were infused on day 12 or day 100. These data suggest that T- cell expansion following adoptive 
transfer may be time-dependent with more pro liferation occurring when the cells are infused 
early after lymphoc yte depletion.  
T-cell infusions in these studies were well tole rated with chills/rigors, nausea and low grade 
fevers the most common AEs. Similarly, cyclophos phamide has been safely administered to 
patients with a variety of conditions including autoimmune diseases and infection with HIV 
(Section 1.2) . At the non-myeloablative doses of  cyclophosphamide (200 mg to 2.0 g/m2) that 
will be administered in this study, the adverse effects are read ily managed by routine medical 
interventions such as antieme tics and adequate hydration ( Section 9.2 ). The top dose of 
cyclophosphamide selected for this study, 2.0 g/m2, is below the total cumulative dose of 3.75 
g/m2 that had been safely administered to HIV infected patients in a previous study ( Section 
1.2.3). Collectively, these data suggest that the potential benefit of expanding HIV-1 resistant 
CCR5 modified T-cells may be  greater than the potential adverse effects of low dose 
cyclophosphamide. 
1.5 Study Hypothesis 
The objectives of T-cell imm
unotherapy in people infected with  HIV, are to augment HIV-
specific T-cells and to reverse or decrease the progr essive destruction of CD 4+ T-cells that leads 
to clinical AIDS. SB-728-T has been safely ad ministered to over 60 HI V-infected subjects in 
three clinical trials conducted to date. The level of engraftment has varied from negligible to 
~10% of the CD4+ T-cells in the vascular compartment. Preliminary analyses of HAART TI in the UPENN study suggest that an anti-HIV effect may correlate  with the level of SB-728-T 
engraftment. Concurrently, non-myeloablativ e lymphodepletion with cyclophosphamide has 
been demonstrated to enhance engraftment of a doptively transferred T-ce lls through a variety of 
mechanisms ( Section 1.2 ). The current study is being undertaken to increase SB-728-T 
engraftment through the administ ration of low non-myeloablative doses of cyclophosphamide. 
  
2. STUDY OBJECTIVES 
2.1 Primary Objective 
The prim
ary objective of this study is  to evaluate the safety and tole rability of escalating doses of 
cyclophosphamide administered up to 3 days prior to SB-728-T infusion. 
2.2 Secondary Objectives 
The secondary objectives of th is study are to evaluate: 
1. Effect of escalating doses of cyclophospham
ide on SB-728-T engraftment 
2. Effect of SB-728-T on plasma HIV-1 RNA levels following HAART interruption 
3. Long-term persistence of SB-728-T in peri pheral blood as measured by pentamer PCR 
4. Change in CD4+ T-cell counts in periphe ral blood after treatment with SB-728-T 
5. Change in HIV reservoirs as part of exploratory research 
 
3. STUDY DESIGN 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 17 of 70                                                                                   Version: January 30, 2014 3.1 Overview 
This is a Phase 1, open-label, dose-escalati on, multi-center study. Subjects who satisfy all 
inclusion/exclusion criteria ( Section 4 ) are eligible to participat e in this study. Within each 
cohort, treatment will be staggered so that ea ch subsequent subject cannot be infused with 
cyclophosphamide until at least 2 weeks after the pr eceding subject. Up to 3 days after receiving 
cyclophosphamide, subjects will be infused with 0.5 to 4.0 x 1010 SB-728-T cells. Subjects who 
are aviremic and have CD4 cell counts ≥500 cells/µL will undergo a minimum 16 week TI 
beginning 6 weeks after infusion of SB-728-T. TI  may be extended beyond 16 weeks for subjects 
whose HIV RNA levels ≤ 10,000 copies/mL and CD4 count ≥ 500 cells/µL at the end of the 16-
week TI. Subjects will be followed for 12 months after the infusion. 
Additional research blood collect ion and/or an optiona l leukapheraesis may be performed during 
the study upon sponsor request. 
3.2 Number of Subjects 
Up to 40 avirem
ic HIV-infected subjects on stable HAART will be enrolled  and treated in 5 dose 
cohorts (3-6 subjects/cohort).  
3.3 Dose Escalation 
The decis
ion to dose escalate to the next cohor t will be made by a Safety Monitoring Committee 
(SMC). Safety data through Week 4 from all s ubjects within a cohort will be reviewed by the 
SMC. If one subject within a cohort develops a dose limiting toxicity (DLT) defined as a Grade 3 
non-hematological AE excluding alopecia or Grade 4 hematological AE (all deemed related to cyclophosphamide), 3 additional subjects will be en rolled and treated in that cohort. Dose 
escalation to the next cohort may proceed if th ere is no more than one DLT in a cohort of 6 
subjects. 
3.4 Cohort Expansion  
If no DLT develops in 3 subjects in Cohort 5 (1.5 g/m
2), additional subjects may be enrolled into 
that cohort.   
 
Upon evaluation of data from Cohort 5 (1.5 g/m2), the sponsor may elect to enroll additional 
subjects into C ohort 3 ( 1.0 g/m2).  
3.5 Study Duration 
The duratio
n of study participation will be appr oximately 15 months for each subject divided 
into approximately 3 months for screening, leukapheresis, and SB-728-T production, followed 
by 12 months for treatment and study follow-up.   
3.6 Visit Schedule 
Subjects will com
plete all scr eening procedures then undergo a 10 L leukapheresis to collect 
peripheral blood mononuclear cells for the manufacturing of SB-728-T (approximately 2 
months). Subjects will then receive IV cyclophospha mide up to 3 days prior to the infusion of 
SB-728-T on Day 0 for optimal engraftment. Subj ects in Cohorts 4 and 5 will have additional 
testing on Day 5 and Day 12. Subjects will be se en weekly on Weeks 1 through 4. Subjects will 
then begin a minimum 16-week TI beginning on W eek 6. Subjects will be evaluated at weeks 8, 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 18 of 70                                                                                   Version: January 30, 2014 10, 12, 14, 18 and 22 during the TI. After completion of the 16-week TI or during TI extension 
(Section 9.3), subjects will be seen at Month 7, Month 8, Month 10, and Month 12. 
Upon the sponsor’s reques t, additional blood coll ection and /or an optional leukapheresis may be 
performed during the study. 
3.7 Study Procedures 
Subjects will have periodic blood tests to asse ss safety labs, plasm
a HIV-1 RNA levels and 
CD4+ T-cell counts; physical exams; AE assessmen t; and review of medica tions.  (Appendix I).  
 
4. SUBJECT SELECTION 
4.1 Inclusion Criteria 
1. W
ritten informed consent signed and dated by study subject.   
2. Male or female, 18 years of age or older. 
3. Documented HIV diagnosis.  
4. Adequate venous access and no other c ontraindications for leukapheresis. 
5. Absolute neutrophil count (ANC) >  2500/mm3.  
6. Hemoglobin level ≥ 13 g/dL (males); >  12 g/dL (females). 
7. Platelet count ≥ 200,000/mm3.  
8. Serum creatinine < 1.5 mg/dL. 
9. AST and ALT ≤ 2.5 times the upper limit of normal.  
10. Must be willing to comply with study-mandated evaluations; including only changing antiretroviral regimen when i ndicated by the study doctor during the 
study period.  
11. Female of childbearing potential must ha ve a negative serum pregnancy test at 
screening and negative urine pregnancy test at the baseline visit prior to infusion. 
A female subject is considered to be of childbearing potential if she is postmenarcheal, has an intact uterus and at  least 1 ovary, and is less than 2 years 
postmenopausal.   
12. Have no polymorphisms in the CCR5 ZFN ta rget region as determined by Cel 1 
SNP assay at screening.  
13. All subjects must have received at leas t 6 months of continuous HAART therapy 
and have had undetectable VLs for the preceding 3 months. Subjects who had 
intermittent isolated episodes of det ectable low-level viremia <500 copies 
RNA/mL; blips) will remain eligible. 
14. On stable antiretroviral medication (no changes to treatment within 4 weeks of screening.  
15. CD4+ T-cell count ≥500 cells/µL.  
16. HIV-1 RNA below the limit of assay detection obtained at screening.  
17. Willing to discontinue current antiretroviral therapy during the treatment interruption. 
18. Adenoviral Neutralizing Antibody ≤ 40 
19. Low innate immune system activatio n as determined by the sponsor 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 19 of 70                                                                                   Version: January 30, 2014 4.2 Exclusion Criteria 
1. Acute or chronic hepatitis B or hepatitis C infection.  
2. Active or recent (in prior 6 mont hs) AIDS defining complication. 
3. CXCR4 tropic or dual tropic HIV virus. 
4. Any cancer or malignancy within the pa st 5 years, with the exception of 
successfully treated basal cell or squam ous cell carcinoma of the skin or low 
grade (0 or 1) anal or cervical dysplasia. 
5. Current diagnosis of NYHA grade 3 or  4 CHF, uncontrolled angina or 
uncontrolled arrhythmias. 
6. History or any features on physical examination indicative of a bleeding diathesis. 
7. Previous treatment with any HIV experime ntal vaccine within 6 months prior to 
screening, or any previous gene th erapy using an in tegrating vector. 
NOTE: Subjects treated with placebo in an HIV vaccine or gene therapy study 
will not be excluded if documentation that they received placebo or sham gene therapy is provided. 
8. Use of chronic corticoste roids, hydroxyurea, or imm unomodulating agents (e.g., 
interleukin-2, interferon-al pha or gamma, granulocyte co lony stimulating factors, 
etc.) within 30 days prior to screening. 
NOTE: Use of inhaled or topical steroids is not exclusionary.  
9. Breast-feeding, pregnant or unwilling to use acceptable methods of birth control 
for 6 months following the infusion of SB-728-T cells. 
NOTE: The following are acceptable methods of birth control: 
a. Condoms (male or female) with or without a spermicidal agent  
b. Intrauterine device (IUD)  
c. Diaphragm or cervical cap with spermicide 
d. Hormonal-based contraception 
Subjects who become pregnant after SB-7 28-T infusion must inform the 
investigator of their pregnancy and agree to provide follow-up information at 
time of delivery . 
10. Use of Aspirin, dipyridamole, warfarin or any other medication that is likely to 
affect platelet function or other aspect s of blood coagulation during the 2 week 
period prior to leukapheresis.  
11. Active drug or alcohol use or dependence th at, in the opinion of  the investigator, 
would interfere with adhere nce to study requirements. 
12. Serious illness requiring systemic treatment and/or hospitaliza tion within 30 days 
prior to study entry. 
13. Elevations of baseline serum bilirubin and amylase ≥3 times the upper limit of 
normal.  
NOTE: As
ymptomatic elevations due  to HAART medications are not 
exclusionary, when, in the opinion of th e investigator, the abnormalities are not 
attributable to intrinsi c hepatic disease.   
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 20 of 70                                                                                   Version: January 30, 2014 14. Recent vaccination or intercurrent illn ess (within 5 weeks prior to SB-728-T 
infusion). 
NOTE: it is recommended that subjects should have completed their routine 
vaccinations (hepatitis A or B, pneumoc occus, influenza and tetanus diphtheria 
booster) at least 30 days prio r to screening for the study. 
15. Have an allergy or hypersensitivity to study product excipients (human serum 
albumin, DMSO and Dextran 40). 
16. Currently participating in another clinical  trial or participation in such a trial 
within 30 days prior to  screening visit.  
17. Subjects who are currently ta king maraviroc or have received maraviroc within 6 
months prior to screening. 
18. Any other condition that, in the opinion of  the clinical investigator or sponsor, 
might compromise any aspect of this trial.  
5.  INFORMED CONSENT 
Prior to entering the study, the i nvestigator or designated personne l will explain to each subject 
the nature of the study, its purpose, the procedures, the expe cted duration, alte rnative therapies 
available, and the benefits and risk
s involved in  study participation.  Subjects will be given an 
information and consent document, will have the opportunity to ask questions, and will be 
informed of their right to w ithdraw from the study at any tim e without prejudice. After this 
explanation and before any study -specific procedures have been  performed, the subject must 
voluntarily sign and date the informed consent document. 
The subject will receive a copy of  the signed and dated written informed consent form and any 
other written information required to be provided to the subject. Subjects will be re-consented at 
the time of any informed consent amendment, as  applicable, and will be provided a copy of the 
consent form. 
 
6. STUDY METHODOLOGY 
Prior to initiation of this st udy, the study site must have the protocol and subject inform
ed 
consent form approved by the IRB. Subjects mu st be willing to participate in all study 
procedures in this protocol. The following sections describe a ll study procedures. See Section 7  
for details of evaluations. Additional detailed  instructions will be provided in the Study 
Reference Manual.   
A table of all study procedures is pr esented in the Schedule of Events ( Appendix 1 ).  
6.1 Screening Visit Procedures 
The objec
tive of the screening visit is to identi fy subjects who meet th e stated inclusion and 
exclusion criteria and who ar e willing and able to participate in the study. The following 
screening information and proced ures must be completed and re sults reviewed for eligibility. 
The following will be performed at the screening visit: 
1. Obtain a signed and dated subject informed consent form and authorization 
document to use and disclose medical in formation prior to performing any study-
specific procedures 
2. Assign a subject number 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 21 of 70                                                                                   Version: January 30, 2014 3. Review the inclusion and exclusion criteria 
4. A complete medical history including dem ographic information; access and review 
of concomitant medications. If the subject is not normally seen at the study center, it 
may be necessary to obtain medical records to confirm study eligibility.  
5. Complete Physical Exam  
6. 12-lead ECG 
7. Hepatitis B surface antigen (HBsAG) and he patitis C antibody (HCV) (not required 
if HBsAG or HCV antibody are negative within 60 days of screen visit) 
8. Serum pregnancy test (female of childbearing potential) 
9. Urinalysis for presence of glucose, protei n, bilirubin, blood, pH, a nd specific gravity 
10. CBC with differential, pl atelet count, and ANC 
11. Serum chemistry: electrolytes (Na, K, CO 2, Cl), creatinine, BUN, glucose, uric acid, 
total bilirubin, ALP, ALT (or SGPT), AST (or SGOT), LDH, albumin, calcium, and 
total protein, phosphorus.  
12. CD4+ T-cell counts and CD4/CD8 ratio 
13. HIV-1 RNA  
14. CCR5 SNP Cel-I assay 
15. Ad and SB-728 Immunogenicity 
16. HIV-1 Co-receptor Tropism 
17. Innate immune system activation 
6.2 Subject Enrollment Procedures 
Prior to the first leukapheresis, the study site m
ust verify that the subject meets all inclusion and 
none of the exclusion criteria. A subject is cons idered enrolled after they meet all the entry 
criteria and have undergone the first leukapheresis.   
6.3 Pre- Leukapheresis and Leukapheresis  Subjects
 who meet all the eligibility criteria will be scheduled for leukapheresis. Sangamo 
BioSciences should be contacted by the study center prior to scheduling leukapheresis and 
Sangamo will ensure availability of manufacturing facility.   
6.3.1 Pre-Leukapheresis: 
The following blood tests m
ust be drawn approximately 1 week prior to the leukapheresis 
procedure and results sent to th e Apheresis unit and Sangamo.   
1. CBC with differential and platelet count 
2. Electrolytes (Na, K, C0 2, Cl) 
3. Calcium 
4. Liver function tests (albumin, total protein, alkaline phosphatase, AST, ALT,  total 
bilirubin) 
6.3.2 Leukapheresis: 
From a single 10L volum
e leukapheresis, at least 10 x 109 white blood cells will be harvested to 
manufacture SB-728-T. The leukapheresis procedur e will be conducted accord ing to the facilities 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 22 of 70                                                                                   Version: January 30, 2014 guideline. The cells from the leukapheresis product will be genetically modified and expanded 
using anti-CD3/CD28 beads. The cell product is expected to be ready for release to the study 
center approximately 6-8 weeks later. If the pr oduct from the first leukapheresis does not meet 
cell release criteria or there are insufficient cells for the intended dose, a second leukapheresis 
may be scheduled. The second leukapheresis will  be at least three weeks after the first 
leukapheresis. AEs documented during leuka pheresis will be entered onto the CRFs. 
6.4 Baseline Assessments 
6.4.1  Baseline for Research Blood Collection: 
The following blood tests will be drawn be tween the leukapheresis procedure and 
cyclophospham
ide administration:   
1. CBC with differential 
2. CD4+ T-cell count 
3. Research blood 
6.4.2 Baseline: Baseline a
ssessments will be performed approximately one week prior to cyclophosphamide 
administration, and the subject sh ould be evaluated. The followi ng tests are performed at the 
baseline visit: 
1. Assessment of AEs 
2. Review concomitant medications 
3. Urine pregnancy test (for females of child bearing potential only) 
4. Chemistry 
5. CBC with differential, pl atelet count, and ANC 
6. Urinalysis 
7. CD4+ T-cell count 
8. HIV-1 RNA  
9. Height and Weight  
10. Research blood (may be performed on the day of cyclophosphamide infusion 
and prior to cyclophosphamide infusion) 
The following may be performed up to 4 weeks prior to the SB-728-T infusion 
11. Pentamer assay 
12. Ad and SB-728 immunogenicity  
 
6.5 Study Treatment and Follow-up 
After baseline tests are review ed, the study center will contact Sangam
o BioSciences to schedule 
SB-728-T dosing. Refer to the Study Reference Manua l for details. All subj ects will be followed 
for a total of 12 months after SB-728-T infusi on according to the schedule in Appendix 1. 
6.5.1  Cyclophosphamide Administration 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 23 of 70                                                                                   Version: January 30, 2014 Cyclophosphamide should be administered up to 3 days prior to SB-728-T infusion. Subjects 
should consume at least 4L of  fluids over the 24 hrs prior to receiving cyclophosphamide 
(Cohorts 4 and 5 only). All subjects will rema in at the study site after cyclophosphamide 
administration until vital signs are satisfactory and stable. Subject may be released from the 
study site at investigator’s discretion. Subjects in  Cohorts 4 and 5 will have additional testing of 
CBC (with differential), platelet count, and ANC on Day 5 and Day 12. Subjects will be 
monitored, as needed, post cyclophosphamide administration.  
1. AE assessment 
2. Assessment of concomitant medications 
3. Vital signs: temperature, pulse, and blood pressure (pre and post cyclophosphamide 
administration) 
Pre-Cyclophosphamide administration: 
4. Chemistry 
5. CBC with differential, pl atelet count, and ANC 
6. Urinalysis 
7. CD4+ T-cell count 
8. Volume status of subject will be asse ssed to ensure subject is euvolemic 
9. Euvolemic subjects will be infused IV with  1L of IV fluids over approximately 1-2 
hours. 
10. Antiemetic administration: Subjects may be prescribed with an antiemetic (IV, oral 
or suppository) before, during, and after cy clophosphamide infusion to prevent and 
treat nausea and vomiting. Recommended an tiemetic regimen: Palonosetron (Aloxi) 
0.25 mg IV and Aprepitant (Emend) 125 mg by mouth (PO) 60 minutes before cyclophosphamide. Other antiemetics may be given at the discretion of the 
investigator and with sponso r consultation if possible. 
Cyclophosphamide Administration: 
11. Cyclophosphamide administration 
Post-Cyclophosphamide Administration: 
12. 1L of IV fluids infused over approximately 1-2 hrs after cyclophosphamide administration  
13. Subjects in Cohorts 1-3 should consume at least 4L of fluids over the 24 hrs after 
receiving cyclophosphamide. Subjects in Cohorts 4 and 5 should consume 4L of 
fluids per day over the next 7 days. 
14. Subjects will be sent home with urine dipsticks and are to test their urine twice daily (once in the morning and again in the ev ening) for 7 days following administration 
of cyclophosphamide. Subjects are to call the study center if any hematuria is detected. (Cohorts 4 and 5 only) 
15. Recommended antiemetic regimen: Aprepita nt (Emend) 80mg PO daily (QD) for the 
following 6 days. Other antiemetics may be give n at the discretion of the investigator 
and with sponsor consultation if possible. 
 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 24 of 70                                                                                   Version: January 30, 2014 Subjects in Cohorts 4 and 5 will have additiona l testing of CBC (with differential), platelet 
count, and ANC on Day 5 and Day 12. 
 Post cyclophosphamide administrati on, if neutrophil count drops to ≤ 750/mm
3, 
administration of Filgrastim is recomme nded. Filgrastim can be discontinued when 
neutrophil count is ≥ 1000/mm3 (Section 8.2 ). 
6.5.2 Day 0 – SB-728-T infusion 
All subjects will rem
ain at the study site for approximately 2 hours after SB-728-T infusion and 
vital signs are satisfactory and stable. SB-728-T should be infuse d up to 3 days after completion 
of the cyclophosphamide administration. (Section 8.1) 
1. AE assessment 
2. Assessment of concomitant medications 
3. Vital signs: temperature, pulse, and blood pressure (pre and post SB-728-T infusion) 
Pre-SB-728-T Infusion: 
4. Chemistry 
5. CBC with differential, pl atelet count, and ANC 
6. Urinalysis 
7. CD4+ T-cell count 
8. Research blood 
SB-728-T Infusion: 
9. SB-728-T infusion (0.5 to 4.0 x 1010 cells) 
6.5.3 Day 1 
1. AE assessment  
2. Chem
istry 
3. CBC with differential, platelet count, and ANC  
4. Urinalysis 
5. CD4+ T-cell count 
6. Pentamer assay 
7. Research blood 
6.5.4 Day 5 (- 1 day) (Cohorts 4 and 5 only)  
1. CBC with differential, platelet count, and ANC  
6.5.5 Week 1, Day 12 (-1 day) (Cohorts 4 and 5 only) , Week 2, Week 3, and Week 4 (+/- 
2 day) 1. AE assessment 
2. Review of concomitant medica tions (weekly visits only) 
3. Chemistry (Weeks 1 and 3 only) 
4. CBC with differential, pl atelet count, and ANC 
5. Urinalysis (Weeks 1 and 4 only) 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 25 of 70                                                                                   Version: January 30, 2014 6. CD4+ T-cell count (weekly visits only) 
7. HIV-1 RNA (weekly visits only) 
8. Ad and SB-728 immunogenicity (Weeks 1 and 4 only) 
9. Pentamer assay (weekly visits only) 
10. Research blood (Week 2 only) 
6.5.6 Weeks 6, 8, 10, 12, 14, 18 and 22: 16-Week  HA ART Treatment Interruption 
All subjects with aviremia and CD4 cell counts ≥500 cells/µL will undergo a minimum 16-week 
TI. Subjects will be seen every other week (+/- 3 days) for th e first 8 weeks (weeks 6, 8, 10, 12, 
14) and then every month (+/- 1 week) for the remaining 8 weeks of the TI (weeks 18 and 22). 
(Section 8.3 ) 
Subjects will discontinue HAART under the supe rvision of the principal investigator. Non-
nucleoside reverse transcriptase i nhibitors (NNRTI) such as Rescri ptor, Sustiva, Intelence, and 
Viramune have been reported to have a longer half life than nucleosid e reverse transcriptase 
inhibitors (NRTI). Therefore, to avoid s uboptimal drug exposure which may promote drug 
resistance, subjects on a NNRTI containing regimen should discon tinue the NNRTI seven days 
before stopping their other antiretrovirals (Taylor et al., 2007). The time of medication 
interruption is noted in medicati on records and CRFs. The TI begins  for an individual subject on 
the day that all antiretrovirals agents have been discontinued.  
The following procedures will be performed at each visit during the TI: 
1. Begin TI (discontinue all HAART) (Week 6) 
2. AE assessment 
3. Assessment of concomitant medications 
4. Vital signs (temperature, pulse, blood pr essure, and weight) (Weeks 6 and 22 only) 
5. Chemistry (Weeks 6, 8, 12, 18, and 22 only) 
6. CBC with differential an d platelet count  
7. CD4+ T-cell (during the initial 16 week TI, test will be repeated every 2 weeks for 
3 consecutive measurements for values <500 cells/µL) 
8. HIV-1 RNA (during the initial 16 week TI, test will be repeated every 2 weeks for 
3 consecutive measurements for values >100,000 copies/mL) 
9. HIV-1 coreceptor tropism and resistance testing will be performed once if HIV 
RNA exceeds 1,000 copies/mL 
10. Pentamer  
11. Ad and SB-728 immunogenicity (Week 12 only) 
12. Research blood (Weeks 6, 14, and 22 only) 
At the end of the 16-week TI at Week 22: 
• HAART will be reinstituted in subjects w ith HIV RNA levels >10,000 copies/mL and/or 
CD4 <500 cells/µL.    
• Subjects with HIV RNA levels ≤ 10,000 copies/mL and CD4 count ≥ 500 cells/µL may 
elect to remain off HAART and undergo ex tended TI beyond 16-weeks (subjects with a 
VL that is below the limit of detection will remain off HAART). ( Section 8.3 ) 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 26 of 70                                                                                   Version: January 30, 2014 During extended TI, HAART will be reinstituted wh en one or both of the following criteria are 
met: 
• HIV RNA levels > 10,000 copies/mL, confirmed by two additional consecutive monthly 
measurements (for a to tal of 3 measurements) 
• CD4 count < 500 cells/µL, confirmed by an ad ditional consecutive monthly measurement 
(for a total of 2 measurements) 
Subjects will not be put back on HAAR T until all results are available.  
Subjects may have HAART reinstituted at any time  at the discretion of the subject and/or PI. 
6.5.7 Month 7, Month 8, Month 10, Month 12 (+/- 1 week) 
1. AE assessment 
2. Assessm
ent of concomitant medications 
3. Complete Physical Exam (Month 12 only) 
4. Vital signs (temperature, pulse, blood pressure, and weight) (Month 8 only) 
5. Chemistry (Months 7, 10 and 12 only) 
6. CBC with differential and platelet count 
7. Urinalysis (Months 7 and 12 only) 
8. CD4+ T-cell count 
(For subjects in extended TI, test will  be repeated monthl y for a total of 2 
consecutive measurements if  CD4 count <500 cells/µL) 
9. HIV-1 RNA (For subjects in extended TI, test will  be repeated monthl y for a total of 3 
consecutive measurements if HI V-1 RNA levels > 10,000 copies/mL) 
10. Pentamer (Months 8 and 12 only) 
11. Ad and SB-728 immunogenici ty (Months 7 and 12 only) 
12. Research blood  
 
The following additional study procedures ma y be performed upon re quest of sponsor:  
1. Additional Research Blood co llection of 80 mL one or two times. The second blood 
collection of 80 mL will be performed only when insufficient cells are obtained from 
the first collection. If any subject agrees to undergo op tional leukapheresis in the 
study, this research blood collection of 80 mL will not be performed.  
a. Blood collection for CBC with diffe rential and CD4+ T-cell counts 
b. 80 mL blood collection 
2. Optional leukapheresis  
Subject who agrees to an optional leukapheresis will undergo the following additional 
study procedures:  
• Pre-Leukapheresis Visit:  ≤ 7 days prior to the leukapheresis procedure, the 
following blood tests will be performed and results sent to the apheresis facility 
and Sangamo: 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 27 of 70                                                                                   Version: January 30, 2014 a. CBC with differential, platelet count 
b. Electrolytes (Na, K, C0 2, Cl) 
c. Calcium 
d. Liver function tests (albumin, tota l protein, alkaline phosphatase, AST, 
ALT,  total bilirubin) 
e. CD4+ T-cell counts (The test will be performed only if the leukapheresis 
center cannot collect this blood sample) 
• Leukapheresis Procedure Visit: The following will be performed:  
a. CBC with differential and CD4+ T-cell c ounts (prior to the leukapheresis). 
If the leukapheresis center cannot co llect the blood sample, this blood 
collection should be done at th e pre-leukapheresis visit.  
b. a 10L volume leukapheresis procedure will be conducted according to the apheresis facility guidelines.  
6.5.8 Long-Term Follow-up 
Long term
 follow-up for this study will be conducted  under a separate protocol.  At the time of 
informed consent for this protocol, subjects will be made aware of the long term follow-up 
requirement.  
7.  INSTRUCTIONS FOR EVALUATIONS 
 Com 
plete Physical Exam : a complete physical examination must include at a minimum 
an examination of the skin, head, mouth, a nd neck; auscultation of the chest; cardiac 
exam; abdomen; examination of the lower extremities for edema; and a breast exam for 
females. The complete physical exam will al so include vital signs (temperature, pulse, 
blood pressure)(weight and height at  Screen and Baseline Visits). 
 CBC : Hemoglobin, hematocrit, platelet count, red cell count, and wh ite cell count with 
differential count including absolute neut rophil count at screening and baseline.  
 Chemistry : Bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), sodium, pota ssium, chloride, bicarbonate, urea nitrogen, 
creatinine, total protein, album in, calcium, and phosphorous.  
 Hepatitis B : subjects must have documentation of a negative HBsAg test  within 60 days 
prior to study entry.  Subject s who have not previously had the test or subjects who were 
negative more than 60 days prior will have a test at screen prior to leukapheresis. 
 Hepatitis C : subjects must have documentation of a negative HCV antibody test within 
60 days prior to screening. Subj ects who have not previously ha d the test or subjects who 
were negative more than 60 days prior to screening will have a HCV antibody test at 
screening and results  must be reviewed prior to leuk apheresis.  If the HCV antibody is 
positive, the subject may return for a HCV RNA test.  If the HCV RNA test is negative, the subject may undergo leukapheresis.  HCV RNA must be by any RT-PCR or bDNA 
assay performed by a laboratory with a CLIA certification or its e quivalent and results 
evaluated prior to leukapheresis. The test is  not required if documentation of a negative 
result of a HCV RNA test performed within  60 days prior to screening is provided. 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 28 of 70                                                                                   Version: January 30, 2014  HIV-1 Co-receptor Tropism and Resistance Testing : the HIV-1 co-receptor tropism assay 
measures whether a patient has CCR5, CXCR4 or dual tropic virus.  The tropism assay 
looks at the surface receptors on HIV to de termine the dominant co-receptor. Resistance 
testing will be performed using a highly accura te HIV drug resistance test that provides 
the complete picture of resistance and co mbines actual phenotype and genotype drug 
resistance data. The report will include drug resistance information for all of the approved 
NRTIs, NNRTIs, and protease inhibitors.  
 
8.  MEDICATIONS 
8.1 SB-728-T 
SB-728-T is autologous CD4+ T-cells m
odified  at the CCR5 gene by ZFN expressed by SB-728, 
a replication deficien t adenoviral vector.  Autologous CD4+ T lymphocytes are transduced ex 
vivo with SB-728 adenoviral vector. The final T- cell product, SB-728-T, is generated using 2 
major elements: 1) a replication deficient chimeric Ad5/F35 ade noviral vector SB-728, used as 
an accessory product for gene delivery of CCR5  specific zinc finger nucleases and 2) CCR5 
modified autologous CD4+ T-cells (SB-728-T) that  have undergone ex vi vo T-cell activation, ex 
vivo genetic modification by the SB-728 vector, expansion and formulation.  The composition of 
the final T-Cell product is:   
Composition of SB-728-T 
Component Unit Formula  
SB-728 Treated CD4+ T-cells 0.5-1.25 x 1010/100 mL 
PlasmaLyte A 31.25% 
Dextran 40 and 5% Dextrose 10% 
25% Human Serum Albumin 20% 
Dimethyl Sulfoxide (DMSO) 7.5% 
Dextrose 5%/.45% NaCl 31.25% 
 
The final drug product is tested for identity, cell count, purity, viability, potency, mycoplasma, 
endotoxin, and sterility. Cells that have not met specifications or will not be infused will be 
destroyed by the manufacturer according to their procedures. A copy of the Certificate of 
Analysis (C of A) will accompany each infusion bag.  A copy of the C of A and an addendum to 
the C of A that report the cell viability will be sent with each subsequent lot. 
8.1.1  Inventory, Storage, and Handling of the Drug Product 
SB-728-T is cryopreserved in a 500 mL cryocyte infusion bag at ≤ -130◦C.  The infusion bags 
will contain approximately 50 mL of T-cells (actual volume dependent on number of cells) and 
have a label affixed containing the following information: protocol number, subject study 
number, lot number and “FOR  AUTOLOGOUS USE ONLY”. Each bag of cryopreserved 
genetically modified CD4+ T-cells will contain approximately 0.5-1.0 x 1010 cells at a 
concentration of approximately 1 x 108 cells/mL of infusible cryomedia.   
The CCR5 ZFN-modified T-cells are not released from the manufact urer until the release criteria 
for the infused cells are met. Release tests are pe rformed in process, on the pre-harvest cells, and 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 29 of 70                                                                                   Version: January 30, 2014 on the final cryopreserved product. QC testing w ill be performed by Sangamo BioSciences, Inc. 
and commercial testing laboratories, prior to ad ministration of cells to the subject. Quality 
control test results and documentation will be reviewed by external Qual ity Assurance personnel. 
The final release test for cell viability by Trypa n Blue will be performed approximately 72 hours 
before the scheduled thaw and infusion. The C of  A will include the actual number of cells and 
volume contained within the infusion bag. The T- cell product will be st ored frozen at the 
manufacturing facility until ready to be shipped to the clinical study center. The T-cell product 
and the C of A will be shipped frozen either via courier or overnight to the clinical study center 
prior to the scheduled infusion. The T-cell produc t should remain frozen at the clinical study 
center until successful placement of the IV infusion line into the subject. 
The T-cell product is considered biohazard material  therefore if any CCR5 ZFN-modified T-cells 
are not infused, the infusion bag and tubing will be disposed of according to the study center’s 
procedures for safe handli ng of biological material. 
Accessibility to labeled T-cell product should only be to those indivi duals authorized by the 
investigator to dispense this study drug. 
The study center is requi red to maintain comp lete records of all study products received. 
Inventory will include the description of labeled product received during the course of this study, 
as well as a record of the labeled product th at is dispensed. At the c onclusion or termination of 
this study, return or destruction of all drug supplies must be coordinated with Sangamo 
BioSciences. Refer to the Study Refere nce Manual for additional details. 
The investigator ag rees not to supply  labeled product to any person other than study personnel 
and subjects in this study. 
8.1.2 SB-728-T Administration 
Side effects following SB-728-T cell infusions include  trans
ient fever, chills, and/or nausea. It is 
recommended that the subject be pre-medicat ed with acetaminophen 650 mg by mouth and 
diphenhydramine hydrochloride (Benad ryl) 25-50 mg by mouth or IV, prior to the infusion of 
SB-728-T. These medications may be repeated every 3-4 hours as needed. A course of non-
steroidal anti-inflammatory medication may be prescribed if the s ubject continues to have fever 
not relieved by acetaminophen. It is recommended that subjects not receive systemic 
corticosteroids such as hydrocortisone, pr ednisone, prednisolone (Solu-Medrol) or 
dexamethasone (Decadron) at any time, except in the case of a life-thr eatening emergency, since 
this may have an adverse effect on T-cells. If co rticosteroids are required for an acute infusion 
reaction, an initial do se of hydrocortisone 100 mg is recommended. 
SB-728-T will be shipped to the study site prior to the scheduled infusion. SB-728-T should be infused up to 3 days after completion of the cyclophosphamide administration. The study product 
should be thawed just pr ior to the scheduled infusion. Prior to  the infusion, two individuals will 
independently verify all information in the presence of the subject to confirm that the information is correctly matched to the subject.  The cell product should be infused within 15 
minutes after it is thawed and before the solution becomes warm in the IV bag to ensure viability 
of infused cells.  Detailed inst ructions for the thaw and infu sion of cells are in the Study 
Reference Manual. 
8.1.3 Precautions 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 30 of 70                                                                                   Version: January 30, 2014 SB-728-T is an investigational product, and there is a possi ble risk of anaphylaxis. Emergency 
medical equipment will be ava ilable during the infusion in case the subject has an allergic 
response, or severe hypotensive crisis, or an y other reaction to the infusion. Vital signs 
(temperature, pulse, blood pressure) will be taken before and after infusion, then according to the 
study center procedures for a minimu m of two hours. The subject will  be asked to remain in the 
study unit until the study staff consider s it safe for him/her to leave. 
In the unlikely event that the subject develops sepsis or systemic bacteremia following SB-728-T 
infusion, appropriate cultures and medical management shoul d be initiated. If possible 
contamination of the SB-728-T product is suspect ed, the product can be retested for sterility 
using archived samples that are stored at the manufacturing facility. 
As the transmission of HIV and other blood-bor ne pathogens can occu r through contact with 
contaminated needles, blood and blood products, appropriate blood and secretion precautions 
should be employed by all personn el in the drawing of blood and shipping and handling of 
specimens for this study, as currently recommended by the Centers for Disease Control and Prevention and the National Institutes of Health. 
All dangerous goods materials, including diagnostic  specimens and infectious substances, must 
be transported according to th e instructions detailed in the International Air Transport 
Association (IATA) Danger ous Goods Regulations. 
8.1.4 Dose Modifications 
No dose m
odifications are possible si nce this is a single infusion study. 
8.2 Cyclophosphamide Cyclophospham
ide is a sterile white powder c ontaining cyclophosphamide monohydrate. It is 
available in vials of 500 mg, 1.0 g and 2.0 g vials for single use onl y. The vials should be stored 
at 25◦C. Cyclophosphamide should be administered up to 3 days prior to SB-728-T infusion. The 
following doses of cyclophosphamide will be in fused IV:  Cohort 1 (200 mg), Cohort 2 (0.5 
g/m2), Cohort 3 (1.0 g/m2), Cohort 4 (2.0 g/m2), and Cohort 5 (1.5 g/m2).   
Subjects may be pre-medicated with acetam inophen 650 mg by mouth and diphenhydramine 
hydrochloride (Benadryl) 25-50 mg by mouth or IV , prior to the infusion of cyclophosphamide. 
These medications may be repeated every 3-4 hours as needed.  
Antiemetics 
Recommended antiemetics such as Aloxi 0.25 mg IV and Emend 125 mg PO should be given 60 
minutes before cyclophosphamide followed by Emend 80mg PO once a day for the following 6 days. Other antiemetic regimens may be given at  the discretion of the investigator and with 
sponsor consultation, if possible.  Subjects may be prescribed with an antiemetic (IV, oral or suppository) if nausea and vomiting develops during cyclophosphamide administration.  
Filgrastim 
After cyclophosphamide administrati on, if neutrophil count drops to ≤ 750/mm
3, administration 
of Filgrastim is recommended. Filgrastim can  be discontinued when neutrophil count is ≥ 
1000/mm3. 
The adverse effects of cyclophosphamide that occu r at a frequency of >10% are discussed in 
Section 9.2. 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 31 of 70                                                                                   Version: January 30, 2014 Please refer to the FDA approved manufacturer ’s package insert and the Study Reference 
Manual for additional information. 
8.3 HAART 
8.3.1 Discontinuation of HAART  
Subjects with avirem
ia and CD4 cell counts > 500 cells/µL at Week 6 will discontinue HAART 
under the supervision of the principal investigator dur ing the TI. NNRTIs such as Rescriptor, 
Sustiva, Intelence, and Viramune have been re ported to have a longer half life than NRTIs. 
Therefore, to avoid suboptimal  drug exposure which may promot e drug resistance, subjects on 
an NNRTI containing regimen should discontinue the NNRTI seven days before stopping their 
other antiretrovirals (Taylor et  al., 2007). The time of medica tion interruption is noted in 
medication records and CRFs. 
8.3.2 Reinstitution of HAART 
During the 16-week TI, tests for HIV-RNA and CD4 count wi
ll be repeated in 14 days for values 
>100,000 copies/mL and <500 cells/µL, respectively. HAART therapy will be reinstituted if the 
subject experiences a sustained VL increa se to >100,000 copies/mL (on 3 consecutive 
measurements tested every 2 weeks) and/or a sustained drop  in the CD4 count <500 cells/µL (on 
3 consecutive measurements tested every 2 w eeks). The drug regimen that the subject will 
receive will be determined by the Principal Inve stigator in consultation with the subject’s 
primary HIV physician. To guide the selection of therapy, the tropism and se nsitivity of the virus 
to antivirals will be determined by HIV-1 corece ptor and resistance test ing, respectively. If the 
VL or CD4 drop is not sustained, the subject will be advised not to reinstate HAART until after 
the TI to allow for evaluation of the subject’s VL. 
At the end of the 16-week TI at Week 22: 
• HAART will be reinstituted in subjects with HIV RNA levels >10,000 copies/mL, 
and /or CD4 <500 cells/µL.  
• Subjects with HIV RNA levels ≤10,000 copies/mL and CD4 count ≥ 500 cells/µL 
may elect to remain off HAART and unde rgo extended TI beyond 16 weeks (subjects 
with HIV RNA levels below the limit of detection will remain off HAART).   
During extended TI, HAART will be reinstituted in  subjects when one or both of the following 
criteria are met: 
• HIV RNA levels > 10,000 copies/mL, confirmed by two additional consecutive monthly measurements 
• CD4 count < 500 cells/µL, confirmed by an additional consecutive monthly 
measurement 
Subjects will not be put back on HAAR T until all results are available.  
Subjects may have HAART reinstituted at any time  at the discretion of the subject and/or PI. 
8.4 Concomitant Medication 
The investig
ator will record all concomitant me dications including those given in treatment of 
AEs on the concomitant medication page in the subject’s case report form . Any medication taken 
by the subject from screening throughout the c ourse of the study, incl uding over-the-counter 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 32 of 70                                                                                   Version: January 30, 2014 medicinal products, dietar y supplements, and herbal medications , should be recorded on this 
form. 
Aspirin, dipyridamole, Plavix, warfarin, or any other medications likely to affect platelet 
function or other aspects of bl ood coagulation are prohibited dur ing the 2-week period prior to 
leukapheresis.  
Oral corticosteroids, hydroxyurea, and imm unomodulating agents are prohibited until 
completion of this study. A brief course (< 1 week ) of oral corticosteroids is allowed on study. 
Routine vaccines are prohibited for six months  following infusion of cells, unless medically 
indicated. 
 
9.  SAFETY AND POTENTIAL RISKS 
9.1 SB-728-T 
SB-728-T at doses ran
ging from 5 to 40 billi on cells has been safely administered to 
approximately 60 HIV-infected subjects in four c linical trials to date. The longest duration of 
follow-up has been over 3 years in the first subject infused. There was one SAE to date, cellulitis 
and MRSA-abscess of left arm, grade 3, unrelat ed to study drug. It occurred approximately 9 
months after the SB-728-T infusion. Most of the AEs have been mild  to moderate in severity and 
the majority were related to SB-728-T infusion. These include chills, fever, headache, myalgia, 
sweats, dizziness, fatigue, and a “garlic” body odor. All AEs resolved  without sequelae.  
9.1.1 Emergence of CXCR4 HIV  
There is a theoretical possibility that CXCR4 vi ral variants may emerge  following inhibition of 
CCR5. CXCR4 variants are more common in la te stage HIV infection. Even if the CCR5 
depleted cells results in relative selection of low levels of CXCR4 variants, the antiretroviral 
treatment regimen will be able to maintain viral suppression therefor e it is not expected that this 
will be a problem of clinical si gnificance. Subjects in this study w ill be tested for presence of 
dual tropic or CXCR4 tropic viru s prior to entering into the st udy and any subjects with evidence 
of dual or CXCR4 tropism will be excluded. During the TI, a sample will be sent for the HIV-1 
coreceptor assay to asses for CXCR4 or dual tropism when the VL increases to > 1,000 copies/mL. Subjects with a CXCR4 or dua l tropic virus will be  restarted on HAART. 
9.1.2 Carcinogenicity 
There is a risk that p
eople who receive gene transfer may develop new tumors derived from their 
genetically modified cells. This risk is primarily associated w ith viral gene transfer vectors that 
integrate into the cellular DNA where they may dysregulate genes contro lling proliferation. The 
risk with non-integrating adenovi ral DNA gene transfer is extrem ely low. Extensive preclinical 
safety studies have been carried out and s upport the safety of SB-728 ZFNs, are briefly 
summarized here and are recently published in  Nature Biotechnology (P erez et al, 2008). Deep 
sequencing studies at genome sites chosen by thei r ability to bind to the SB-728 ZFNs with up to 
2 base mismatches have shown that the SB-728  ZFNs effect cleavage only at the target CCR5 
gene and at approximately one tenth the CCR5 rate at the highly homologous site of the CCR2 
gene.  Extremely low levels of m odification are also seen in the intron of a third gene, ABLIM-2 
at an extremely low frequency of <1 in 18,000 genes. This data confirms the specificity of SB-
728 to the CCR5 gene. No SB-728 specific effect s on cell growth have been observed, indicating 
that in vitro SB-728 ZFN modifi cation does not appear to affect cell biology and replication.  
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 33 of 70                                                                                   Version: January 30, 2014 Overall increases in double stranded DNA break s as visualized by fluorescence microscopy has 
shown a transient increase just after ZFN treatme nt, which is self limiting, occurs at the time and 
level of expected CCR5 specific ZFN activity and is below the level induced by etoposide, which 
blocks topoisomerase II leading to DNA breaks during cell division. No T cell transformation 
has been detected in a soft agar transformation a ssay, or in multiple animal biotoxicity studies in 
which each animal received greater than the equi valent of a human dose, and over all animals a 
log equivalent of a human dose was evaluated. Ta king this data together, there is currently no 
indication that SB-728 modifi ed T-cells is unsafe and may cause T-cell tumors.  
9.1.3 Replication Competent Adenovirus (RCA) 
The A5/F35 SB-728 vector used in this study is derived from the common cold adenovirus. SB-
728 is tested for presence of RCA and m
eets FDA specification of less than 1 RCA in 3 x 1010 
vector particles. The tropism of this adenoviral v ector is that of Type B adenoviruses, and it is 
more efficient at transduci ng hematopoietic cells than th e more commonly used Type C 
adenovirus (Ad5).  
Previous experience has shown th at systemically distributed re plication competent adenovirus 
vectors (Ad5) induce elevated liv er enzymes at the dose of 6x1012 vector particles and that the 
lethal dose is 1x1014 vector particles when administered systemically (Small et al., 2006a). The 
current protocol will use approximately 6x1012 viral particles to transduce T-cells ex vivo.   
However, at the completion of the ex vivo T- cell culture expansions, there is a significant 
reduction of the level of adenovirus in the T-cells. Preclinical data indicate s that during the 8 to 
10 days of culture of the T-cel ls after transduction with SB- 728, there is at least a 4,000-fold 
reduction of detectable adenoviral genomes by PCR at cell harvest.  Previous studies with the intentional systemic administration of replication competent but 
selective adenovirus has shown ci rculating virus for up to 29 days at IV doses of  3 x10
 12 and 6 
x10 12 vector particles and, with the concomitant deve lopment of high levels of  neutralizing anti-
adenoviral antibodies in all subjects by day 28. This was asso ciated with self limited and 
asymptomatic increases in liver function tests (Small et al., 2006b). There has been no evidence 
of hepatitis in the 35 subjects treated to date. N onetheless, subjects participating in the study will 
be monitored carefully for liver function abnormalitie s and signs or symptoms of hepatitis.  
Subjects in this study will be ev aluated for replication competen t adenovirus (by an E1 gene 
PCR assay), as well as adenovi rus neutralizing antibody titers. Th e clearance of any adenovirus 
(whether replication deficient or  competent) should be quite rapid since most subjects will have 
preexisting antibodies to the Ad 5 penton base and hexon proteins.  
9.1.4 Immunogenicity 
The Ad5 fiber 35 vector util izes AD5 hexon and penton capsi d proteins and the AD 35 fiber 
capsid protein (Nilsson et  al. 2004). Pre-existing neutralizing anti bodies to Ad5, which is the 
most prevalent adenoviral serotype antibody in  m
an, could be reacti ve to SB-728-T (Aste-
Amezaga et al. 2004). After infusion of SB-728-T, all of the pati ents tested to date have 
developed elevated neutralizing adenovirus anti bodies.  There were no associated AEs.  In 
general, subjects with higher pre-existing antibo dy titer had a lower level of engraftment of SB-
728-T in peripheral blood as measured by Quantitative PCR for a common CCR5 modification 
(pentamer assay, units = number of copies of pe ntamer/1e6 genomes) compared to the subjects 
with low pre-existing antibody levels.   
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 34 of 70                                                                                   Version: January 30, 2014 9.2 Cyclophosphamide 
Cyclophosphamide is associated with a variety of si de effects. The adverse effects that occur at a 
frequency of >10% includes alopecia, infertility, nausea and vomiting, hemorrhagic cystitis and 
bone marrow suppression. Antiemetics will be given prophylactically and as needed for nausea 
and vomiting. Leukopenia is more common than thrombocytopenia and anemia with the onset 7 days after administration and a nadir at 10 to 14 days followed by recovery at 21 days. Subjects 
in Cohorts 4 and 5 will have additional testing of CBC (with differential) , platelet count, and 
ANC on Day 5 and Day 12. After cyclophosphamide ad ministration, if neutrophil count drops to 
≤ 750/mm
3, administration of Filgrastim is recommended. Filgrastim can be discontinued when 
neutrophil count is ≥  1000/mm3. Subjects will be monitored, as needed, post cyclophosphamide 
administration. The majority of the adverse effect s require the administration of high cumulative 
doses of cyclophosphamide  (Section 1.2.2) . 
Hemorrhagic cystitis is a potential untoward effect of cyclophosphamide therapy with the metabolite acrolein implicated as the major urothelial toxin. The incidence of hemorrhagic 
cystitis was reported to be 6% among subj ects who received cyclophosphamide (1.0-1.2 g/m
2) 
for ovarian cancer. At these low doses, the Americ an Society of Clinical Oncology recommends 
administering fluids to induce a diuresis. In this study, subjects in Cohorts 1-3 will be hydrated 
with 1 liter of IV fluids prio r to cyclophosphamide administration and with another liter prior to 
discharge from the study center. Su bjects are instructed to drink 4L  of fluids over the next 24 hrs 
to insure adequate diuresis. Subjec ts in Cohorts 4 and 5 will be in structed to drink 4L of fluids 
over the 24 hrs prior to receiving cyclophosphamide and will receive 1L of fluids administered 
IV over 1-2 hrs immediately prior to cyclophos phamide infusion. At discharge from the study 
center, subjects will be instructed to dri nk 4L of fluids per da y for 7 days following 
cyclophosphamide administration to insure adequate diuresis. Subjects will be instructed to test their urine twice daily for micr oscopic hematuria with urine di psticks and to contact the study 
center immediately if hematuria (either  micro or macro) is detected.  
Cyclophosphamide is a carcinogen and has been associated with malignancies. The risk depends upon the dose administered, other co-administered chemotherapy, use of radiotherapy, treatment 
intensity and duration of therapy. Cumulative dose s totaling 10 g or less has been shown to be 
associated with an incidence of malignancy that  is similar to that of the normal untreated 
population (Baker et al., 1987). Therefore, the low doses (200 mg to 2.0 g/m
2) that will be 
administered in this study ar e unlikely to be  carcinogenic. 
9.3 HAART Treatment Interruption (TI) 
The efficacy and safety
 of HAART interruption for HIV patients has been reviewed by Paton 
(Paton, 2008). Data indicates that th ere is no clinical benefit to pa tients with acute HIV infection 
or those with virologic failure due to multidrug resistance. Indeed, TI may be harmful in patients 
with chronic successfully treated infections. Therefore, TI is currently only recommended in the context of clinical trials. 
The safety of TI has been demonstrated by unpu blished data from the Penn study. In that study, 
six subjects had HAART interrupted beginning 4 weeks after receiving SB-728-T ( Table 9.3-1 ). 
Five of the subjects have completed the TI. HI V-RNA which was below the limit of detection at 
the time of the TI became detectable at 2 to 6 w eeks, peaking at 6 to 8 weeks and then declined 
at 12 weeks. In subjects 1, 2 and 6, the VL dropped 0.5- to 2- log within 4 to 6 weeks and 
declined after reinstitu ting HAART. The TI was halted in S ubjects 3 and 4 as per the stopping 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 35 of 70                                                                                   Version: January 30, 2014 rules. In Subject 3, HAART was reinitiate d because the HIV-RNA increased to >100,000 
copies/mL on three consecutive measurements wh ile Subject 4 was found to be infected with 
dual-tropic HIV. Subject 5 became aviremic 12 weeks following initia tion of the TI; this subject 
was subsequently found to be a CCR 5 delta-32 heterozygote by genotyping. 
 
Table 9.3-1: Plasma HIV-1 RNA (copies/mL) during TI        TI           HAART 
Subject 0 2 wks 4 wks 6 wks 8 wks 12 wks 16 wks 
1 <48 <48 <48 359 33,885 9,596 358 
2 <40 103 4991 100,635 12,149 8,248 <40 
3 <40  353 119,855  189,054 Halted 1131 473 
4 <48 <20 84 57643 163,837 Halted 86 
5 <40 <40 <40 6247 4020 <40 --- 
6 <48 24,604 13,288 80,658 28,628 12,871 --- 
 
Several precautions have been inst ituted in this protocol to insure  subject safety. Subjects will be 
monitored closely during the TI period with study visits every 2 weeks for the first 8 weeks and monthly for the remaining 8 weeks. If the HIV RNA increases to >100,000 copies/mL and/or the 
CD4 count drops to <500 cells/µL,  the tests will be repeated every 2 weeks for a total of 3 
consecutive measurements. HAART will be reinstitu ted in subjects whose CD4 cell counts drop 
to <500 cells/µL and/or whose HIV-RNA increases to >100,000 on three consecutive 
measurements. During extended TI, additional monitoring will be performed as needed for safety.  CD4 T-cell count will be repeated monthly for a total of 2 consecutive measurements if CD4 count <500 
cells/µL and HIV-1 RNA will be repeated monthly for a total of 3 consecutive 
measurements if HIV-1 RNA levels > 10,000 copies/m L. In addition, all subjects infected with a 
CXCR4 virus will resume HAART. The effectivene ss of these stopping rules is demonstrated by 
the reinstitution of HAART in Subjects 3 and 4 in the PENN study cited above. 
It is possible that some patients could experien ce symptoms compatible with retroviral rebound 
syndrome, or rarely, other clinical events that occur before use of HAART (e.g. immune 
thrombocytopenia). The kinetics of viral rebound are well char acterized, typically occurring 
within 2 to 4 weeks following di scontinuation of drug, and viral replication is routinely re-
suppressed with resumption of therapy. 
The psychological risks associated with TI appear to be minimal.  In a survey reported at the 
2002 International AIDS Conference in Barcelon a, study investigators quizzed enrollees about 
their experience in the Spanish Swiss Intermittent  Treatment Trial, and found that the majority 
"viewed their experience positively." Only two stated they would not participate in a similar TI 
trial, compared to 72 that said they definite ly would and 25 who answered that they would 
consider it. In terms of any problems taking HAAR T after interruptions, 73 reported that that it 
was no different, 10 said it felt easier while 17 found it more difficult. Furthermore, fewer side effects were reported upon restarting HAART than when therapy was first initiated (Le Braz et 
al., 2002). 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 36 of 70                                                                                   Version: January 30, 2014 10. ADVERSE EVENTS 
10.1 Adverse Event Reporting Period 
During both
 the treatment and follow-up periods, subjects will be queried and events will be 
assessed at each clinic visit.  Subjects will be  reminded to immediately report any SAE to the 
investigator.  Any study proced ure related AEs that occur from enrollment to initiation of 
treatment will also be recorded. 
10.2 Definitions of an Adverse Event 
An AE is any untoward m
edical occurrence associat ed with the use of a drug in humans, whether 
or not considered drug related. The term “adverse event” could include any of  the following 
events which develop or increase in severity during the course of the study. Examples include: 
• Any sign, symptom, or physical examination fi nding that worsens in nature, severity, or 
frequency compared to baseline. Whether th ought to be related or unrelated to the 
condition under study 
• Any clinically significant laboratory abnormality  or laboratory abnormality that requires 
medication or hospitalization 
• All reactions from study drug, incl uding those occurring as a resu lt of an overdose, abuse, 
withdrawal phenomena, sensitivit y, or toxicity to study drug 
• Concurrent illness 
• Injury or accident 
A pre-existing condition is one that  is present prior to or at the start of the study and is to be 
reported as part of the subject’ s medical history.  It should be reported as an AE only if the 
frequency, intensity, or the character of the condition wors ens during study treatment. 
The term AE also applies to laboratory findings or results of other diagnostic procedures that are 
considered to be clinic ally relevant (e.g., that required un scheduled diagnostic procedures or 
treatment measures, or resulted in withdrawal from the study). 
 
Suspected Adverse Reaction is any AE for which there is a reasonable possibility that the drug 
caused the AE. “Reasonable possibility” means there is evidence to suggest a causal relationship 
between the drug and the AE. Suspected adverse reaction implies a lesser degree of certainty 
about causality than adverse reaction, which means any AE caused by a drug. 
Unexpected AE or Unexpected Suspected Adve rse Reaction:  An AE or suspected adverse 
reaction is considered “unexpected” if  it is not listed in the inves tigator brochure or  is not listed 
at the specificity or severity that  has been observed; or, if an i nvestigator brochure is not required 
or available, is not consistent with the risk in formation described in the general investigational 
plan or elsewhere in the current application, as amended.  For example, under this definition, 
hepatic necrosis would be unexpected (by virtue of  greater severity) if the investigator brochure 
referred only to elevated hepatic enzymes or he patitis.  Similarly, cerebral thromboembolism and 
cerebral vasculitis would be unexp ected (by virtue of greater specificity) if the investigator 
brochure listed only cerebral vascular accidents.  “U nexpected,” as used in this definition, also 
refers to AEs or suspected adverse reactions that  are mentioned in the investigator brochure as 
occurring with a class of drugs or as anticipated  from the pharmacological properties of the drug, 
but are not specifically mentioned as occurring with the particular dr ug under investigation. 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 37 of 70                                                                                   Version: January 30, 2014 10.3 Recording of an Adverse Event 
The principal investigator is responsible for evaluating all AE s, obtaining supporting documents, 
and determining that documentation of the ev ent is adequate. He/she is responsible for 
determining the severity and relationship to the investigational drug.  The principal investigator 
may delegate these duties to sub-investigators a nd must assure that these sub-investigators are 
qualified to perform these dutie s under the supervision of the principal investigator. 
All AEs will be recorded in the subject's case report  form (CRF).  The detailed description of the 
event will include appropriately graded severity of the AE and its relationship to the study drug. 
Severity will be categorized by toxicity grad e according to the Division of AIDS Table for 
Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), 
Version 1.0, December 2004, Clarification 1.0, August 2009 with the exception of the following: nausea or vomiting will be a Grade 3 non-hematolo gical AE if IV fluids are required for more 
than 24 hours.  AEs not listed in the DAIDS Clinical Trial Toxi city Criteria with the exception of noninfective 
cystitis will be evaluated by using the following criteria:  
• Grade 1, Mild: Symptoms causing no or minimal interference with usual social & 
functional activities  
• Grade 2, Moderate:  Symptoms causing greater  than minimal interference with usual 
social & functional activities  
• Grade 3, Severe:  Symptoms causing inabilit y to perform usual social & functional 
activities 
• Grade 4, Potentially Life-threatening: Symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent 
impairment, persistent disability, or death  
• Grade 5: For any AE where the outcome is death. 
Noninfective cystitis will be graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE) Version 4.03 with the following criteria:  
• Grade 1: Microscopic hematuria; minimal in crease in frequency, urgency, dysuria, or 
nocturia; new onset of incontinence   
• Grade 2:  Moderate hematuria; moderate  increase in freque ncy, urgency, dysuria, 
nocturia or incontinence; urinary catheter placement or bladder irrigation indicated; limiting instrumental activities of daily living (ADL) 
• Grade 3:  Gross hematuria; transfusion, IV medications or  hospitalization indicated; 
elective endoscopic, radiologic or operative intervention indicated  
• Grade 4: Life-threatening consequences; urge nt radiologic or ope rative intervention 
indicated 
• Grade 5: Death 
The relationship of the AE to the investigat ional drug will be determined by the principal 
investigator and will be categorized as:  
• Not Related : Any AE that does not meet the defi nition of a suspect ed AE reaction. 
 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 38 of 70                                                                                   Version: January 30, 2014 All grade 3 and 4 clinical laboratory results that represent an increase in severity from baseline 
will be reported as AEs if it is not associated wi th a diagnosis already reported on the case report 
form.  A grade 1 or 2 clinical laboratory abnorma lity should be reported as an AE only if it is 
considered clinically significant by the investigator. 
In the event of death, the cause of death should be  recorded as the AE and reported as an SAE.  
“Death” is not the AE; “death” is an outcome.  If an autopsy is performed, a copy of the autopsy 
report should be obtained if possible. 
 
11. SERIOUS ADVERSE EVENT 
11.1 Serious Adverse Event Reporting Period 
SAEs, whet
her or not unexpected or considered to  be associated with the use of the labeled 
product, must be communicated to Sangamo BioSci ences upon discovery of the event, either by 
telephone or fax within 24 hours. 
Medical Monitor: Winson Tang, M.D. 
Phone Number: Office : (510) 970-7800  
Mobile: (310) 497-7038  
Assistant to Dr. Tang: Vivian Tran 
Phone Number: (510)-970-6000, extension 200 
Fax Number: (510) 970-6009 
The investigator is responsible for promptly notifying the Institutional Review Board (IRB) in accordance with local regul ations, of all SAEs. The National In stitutes of Health (NIH) requires 
that all investigators participating in gene transf er research report all se rious AEs immediately to 
the FDA, NIH, and Institutional Biosafety Comm ittee. Sangamo BioSciences will assume the 
responsibility for reporting SAEs to the FDA. 
All “serious” events must be followed with appropriate medical management until resolved or 
stabilized.   
11.2 Definitions of a Serious Adverse Event 
Any AE or
 suspected adverse reaction is consider ed “serious” ” if, in th e view of either the 
investigator or sponsor, it results  in any of the following outcomes: 
• Death 
• A life-threatening AE 
• Inpatient hospitalization or prol ongation of existing hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• A congenital anomaly/birth defect in the offspring of an exposed patient 
 
An AE or suspected adverse reaction is considered “life-threatening” if, in the view of either the 
investigator, or sponsor, its occu rrence places the patient or subject at immediate risk of death. It 
does not include an AE or suspec ted adverse reaction that, had it occurred in a more severe form, 
might have caused death). 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 39 of 70                                                                                   Version: January 30, 2014 Important medical events that may not resu lt in death, be life-th reatening, or require 
hospitalization may be considered  serious when, based upon appropr iate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Exam ples of such medical ev ents include allergic 
bronchospasm requiring intensive treatment in an  emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient  hospitalization, or th e development of drug 
dependency or drug abuse. 
With regard to results obtained from tests in laboratory animals or in vitro testing, whether or not 
conducted by the sponsor, a SAE includes any ev ent suggesting significant risk to human 
subjects. 
 
11.3 Recording of a Serious Adverse Event 
SAEs reported by telep
hone must be recorded on a written SAE Report Form, provided by 
Sangamo BioSciences.  The SAE report form must be faxed to Sangamo BioSciences within 24 
hours. 
The medical monitor will then advise the inves tigator regarding the nature of any further 
information or documentation that is required.  Follow-up reports must be submitted in a timely 
fashion as additional information becomes available. 
 12. SUBJECT WITHDRAWAL, DOSE ESCA LATION, AND STOPPI
 NG RULES   
12.1 Subject Withdrawal and Discontinuation from Study  
Subjects should be discontinued from study for any of the following reasons: 
 Request by the subject to withdraw. 
 Request of the sponsor or prim
ary care provid er if he or she thinks the study is no 
longer in the best inte rest of the subject. 
 Pregnancy prior to SB-728-T infusion. 
 Subject judged by the investigator to be at significant risk of failing to comply with 
the provisions of the protocol as to cause ha rm to self or seriously interfere with the 
validity of the study results. 
 At the discretion of the IRB, Office fo r Human Research (OHR), Food and Drug 
Administration (FDA), investigator, or Sangamo. 
Subjects will be strongly encouraged to conti nue with follow-up safety evaluations if they 
withdraw consent. If a subject discontinues from  the study a conference between the investigator 
and medical monitor will take place to ensure th at all subjects will comply with the follow-up 
safety evaluations of the prot ocol. Subjects will be assessed  for treatment-related AEs and 
disease status. 
12.2 Dose Escalation Rules 
A SMC will determ
ine if it is safe to dose escala te to the next cohort. If one subject within 
Cohorts 1-5 experiences a DLT defined as a Grade 3 non-hemat ological AE excluding alopecia 
or Grade 4 hematological AE (all deemed related to cyclophosphamide), 3 additional subjects 
will be enrolled and treated in that cohort. Dose  escalation to the next cohort may proceed if 
there is not more than one DLT (all deemed related to cy clophosphamide) in a cohort of 6 
subjects.  Safety data including AEs, clinical laboratory results (che mistry, hematology, CD4 T-
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 40 of 70                                                                                   Version: January 30, 2014 cell counts and VL) through Week 4 from all subj ects within a cohort will be reviewed by this 
group to determine if it is safe to proceed with SB-728-T infusion.  
Treatment of subjects will be sta ggered at least 2 weeks apart. 
12.3 Cohort Expansion  
If no DLT develops in 3 subjects in Cohort 5 (1.5 g/m2), additional subjects may be enrolled into 
that cohort.  
Upon evaluation of data from Cohort 5 (1.5 g/m2), the sponsor may elect to enroll additional 
subjects into Cohort 3 (1.0 g/m2).  
12.4 Stopping Rules  
12.4.1 Stopping Rules for Treatment Interruption  
The TI will be stopped if the subject experien ces a sustained VL increase to >100,000 copies/mL 
(at least 3 consecutive measurements tested ever y 2 weeks) and/or a sustained drop (at least 3 
consecutive measurements tested every 2 week s) in the CD4 count <500 cells/µL during the 
initial 16 weeks of TI. HAART will be reinstituted in these subj ects. The drug regimen that the 
subject will receive will be determined by the Principal Investigator in  consultation with the 
subject’s primary HIV physician. To guide the sel ection of therapy, the tropi sm and sensitivity of 
the virus to antivirals will be determined.  
At the end of the 16-week TI: 
• HAART will be reinstituted in subjects w ith HIV RNA levels >10,000 copies/mL, and 
/or CD4 <500 cells/µL.  
• Subjects with HIV RNA levels ≤10,000 copies/mL and CD4 count ≥ 500 cells/µL may 
elect to remain off HAART and undergo extended TI beyond 16 weeks (subjects with 
HIV RNA levels below the limit of de tection will remain off HAART).   
 
HAART will be reinstituted in subjects, whose TI is extended beyond 16 weeks, when one or 
both of the following criteria are met: 
• HIV RNA levels >10,000 copies/mL, confir med by two additional consecutive monthly 
measurements.  
• CD4 count <500 cells/µL, confirmed by an additional consecutive monthly measurement.   
Subjects may have HAART reinstituted at any time  at the discretion of the subject and/or PI. 
12.4.2 Stopping Rules for Study  
Safety data for subjects in each coho
rt will be  evaluated for consideration of dose escalation by a 
SMC one month after the last SB-728-T infusion in the cohort. Safety data including AEs, 
clinical laboratory results (chemistry, hemato logy, CD4 T-cell counts and VL) will be evaluated. 
Subjects in the subsequent cohort may be screen ed and enrolled prior to the safety review. 
However they will not be infused until the SMC has reviewed the data and approved for dose escalation of that cohort. The SMC w ill convene at any time, as needed.  
The study will be paused if
: 
 There are excessive or unexpect ed toxicities associated wi th the protocol. Specifically, 
the study will be paused if it is determined that two subjects in a cohort (Cohorts 1-5) 
have a non-hematological Grade 3 toxicity  excluding alopecia and/or hematological 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 41 of 70                                                                                   Version: January 30, 2014 Grade 4 toxicity, or if one subject has Gr ade 5 toxicity as determined by the DAIDS 
Clinical Trial Toxicity Criteria of D ecember 2004, Clarification 1.0, August 2009 and 
judged to be related to the study treatment.  The study will be paus ed and available data 
will be evaluated by the SMC.  
 A subject experiences an absolute lymphocyte count grea ter than 10,000 uL, until the 
evaluation of the nature of the lymphocyte incr ease is determined. If it is found not to be 
related to the study treatment, then the study will resume. 
 Confirmed CXCR4 or CXCR4 and CCR5 du al tropic virus: if at least two  subjects 
develop a VL that can be assessed for tr opism (>1,000 copies/mL) and they are both 
either CXCR4 or dual tropic, the study will be paused and available data will be 
evaluated by the SMC.  
The study will be stopped if:  
 The Investigator, Sponsor, SMC, independent safety monitor or regulatory body decides 
for any reason that subject safety may be compromised by continuing the study.   
 The Sponsor decides to discontinue the developm ent of the intervention to be used in this 
study. 
 An analysis of clonal outgrow th of T-cells determines th at it is a result of SB-728-
mediated oncogenesis. 
 Sustained (confirmed) virologic failure without an alternative explanation: If any subject 
develops an increase in HIV-1 RNA of > 5000 copies/mL when not undergoing TI, the 
test will be repeated once a week for an additional 2 weeks. If  the VL remains > 5000 
copies/mL for at least 3 w eeks, and has no alternativ e explanation (such as non-
compliance) other than the study tr eatment, the study will be stopped. 
 
13. STATISTICAL ANALYSIS  AND DATA ANALYSIS 
This is an exploratory study and th us, there will be lim
ited statistic al power to eval uate efficacy 
and related biological endpoints. Therefore, analyses will be primarily descriptive and 
exploratory in nature.  
13.1 Sample Size 
This is a ph
ase 1 study in which three to six ev aluable subjects in each c ohort will be treated to 
evaluate safety of each cyclophosphamide dose leve l. A cohort can be expanded if there is no 
DLT in 3 subjects treated or  no more than 1 DTL in 6 subjects treated in that cohort. In order to 
have an evaluable sample size, subjects who prematurely discontinue the study prior to the 
conclusion of the TI will be replaced with anothe r subject. Safety will be  evaluated after each 
cohort before treating th e next dose cohort. Table 13.1-1  provides the probability of failing to 
observe an AE in a sample size of three or six evaluable subjects, for various underlying true AE 
rates. Thus, only AEs that occur at least 60% of the time are likely to be detected in a cohort of 
three subjects. 
 
Table 13.1-1   
  Probability of Failing to Observe an 
Adverse Event 
True Adverse 
Event Rate  
N=3  
N=6 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 42 of 70                                                                                   Version: January 30, 2014 5% 86% 74% 
10% 73% 53% 
20% 51% 26% 
30% 34% 12% 
40% 22% 5% 
50% 13% 2% 
60% 6% <1% 
70% 3% <1% 
 
Table 13.1-2  shows the exact 95% confidence intervals for possible number of observed safety 
outcomes in three or six subjects. For exampl e, if no AEs are observed in a group of six 
evaluable subjects, we can be 95% confident that the true AE rate is less than 46%. 
 Table 13.1-2 
 Exact 95% Confidence Interval 
# Observed 
Adverse Events  
N=3  
N=6 
0 (  0.0%,   70.1%) (  0.0%,   45.9%) 
1 (  8.4%,   90.6%) (  0.4%,   64.1%) 
2 (  9.4%,   99.2%) (  4.3%,   77.7%) 
3 (29.2%, 100.0%) (11.8%,   88.2%) 
4 – (22.3%,   95.7%) 
5 – (35.9%,   99.6%) 
6 – (54.1%, 100.0%) 
  
13.2 Statistical Methods/Data Analysis 
All tab
les, listings, and data summaries will be performed in SAS version 9.2 or later. 
13.3 Intent-to-Treat Population All subjects enrolled in
 this study who receive any portion of  the SB-728-T infusion will be 
included in the intent-to-treat population. 
13.4 Demographics 
De
mographic and baseline characteristics wi ll be summarized by treatment cohorts.   
13.5 Endpoints and Analysis Since this is
 a dose ranging study to evaluate safety, efficacy analyses will be descriptive and 
exploratory in nature. Continuous  variables will be summarized by means, standard deviations, 
medians and ranges by cohort. Categorical vari ables will be summarized with counts and 
percentages per category by cohort.  
13.5.1 Primary Endpoint 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 43 of 70                                                                                   Version: January 30, 2014 Safety assessment will occur on all subjects who received cyclophosphamide. All reported AEs 
will be coded to a standard set of terms using the Medical Dictionary for Regulatory Activities 
(MedDRA) AE dictionary. The frequency of each  event will be summarized by severity and by 
relatedness to the study treatment. 
Terminations, premature withdrawals, AEs, concom itant medications, and la boratory data will be 
tabulated. Laboratory data will be summarized for each time-point that specimens are collected. 
Change-from-baseline values may be calculated for selected laboratory parameters. Shift-tables (change-from-baseline relative to the normal range ) may be constructed for selected laboratory 
parameters.  
13.5.2 Secondary Endpoints 
The secondary endpoints of this study are exploratory in nature and will assess if 
cyclophospham
ide increases SB-728-T engraftment as well as provide ev idence of anti-viral 
activity. These exploratory endpoints may help to define the primary endpoints for future studies. 
1. Effect of escalating doses of cyclophosphamide on SB-728-T engraftment 
2. Effect of SB-728-T on plasma HIV-1 RNA levels following HAART interruption 
3. Long-term persistence of SB-728-T in peri pheral blood as measured by pentamer PCR 
4. Change in total number of CD4+ T-cells in peripheral blood after treatment with SB-728-
T 
5. Change in HIV reservoirs as part of exploratory research 
 
14. INVESTIGATOR OBLIGATIONS 
The investigator will ensure that the study is conducted in com
pliance with the protocol, the 
Declaration of Helsinki and accord ing to ICH Guidelines for Good Clinical Practice (E6) and all 
regulatory and institutional requirements, includi ng those for subject privacy, informed consent, 
Institutional Review Board or Ethics Committee approva l and record retention. 
14.1 Informed Consent 
According to 21 CFR Part 50.20, no investigator m
ay involve a human being as a subject in 
research covered by these regulations unless the investigator has obtained the legally effective 
informed consent of the subject or the subject’s legally authorized representative. An investigator shall seek such consent only under circumstances that provide the prospective subject sufficient 
opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence. The in formation that is given to the subject or the representative 
shall be in language understandable to the subject or the representative. 
Sangamo will provide the investigator with a templa te for the consent form.  State and local laws 
and/or institutional requirements may require the disclosure of additional information in the informed consent. The proposed consent form must be submitted to Sangamo prior to submission to the IRB or IEC to ensure that it m eets Sangamo standards for consent forms. 
The IRB or IEC must approve the consent form. A copy of the approved form must be submitted to Sangamo.  
Prior to the initiation of any procedures re lating to the study, informed consent shall be 
documented by the use of a written consent form  approved by the IRB and signed and dated by 
the subject at the time of consent. A copy of the signed informed consent will be given to the 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 44 of 70                                                                                   Version: January 30, 2014 person signing the form. The investigator must k eep each subject’s signed consent form on file 
for inspection by a regulatory authority at any time. 
14.2 Institutional Review Boar d and BioSafety Committee 
This protoc
ol, informed consent document, and relevant substantive data are to be submitted to 
the appropriate Institutional Review Board (I RB) and BioSafety Committee (BSC) for review 
and approval before the initiation of the stud y. Amendments to the protocol will also be 
submitted to the IRB and BSC (as appropriate) prio r to implementation of the change. A letter 
documenting the IRB/BSC’s approval must be recei ved by the Sponsor prior to initiation of the 
study.  14.2.1. Protocol Amendments 
Any changes to this p
rotocol will be initiated by Sangamo in writing as a protocol amendment. 
The amendment must be submitted to the IRB together with a revised informed consent form, if 
applicable. Written documentation of IRB approval must be received before the amendment may 
take effect. 
14.2.2. Other Reporting Obligations 
The Principal Investigator is also responsible fo r inform
ing their IRB of the progress of the study 
and for obtaining annual IRB renewa l. The IRB must be informed at the time of completion of 
the study. The Principal Investigator should provide their IRB (if required by the institution) with 
a summary of the results of the study. 
14.3 Subject Privacy 
Subject m
edical information obtained for the purposes of this trial is confidential, and disclosure 
to third parties, other than those noted below,  is prohibited. Upon the subject’s request and 
written permission, medical information may be given to his/her pers onal physician or other 
appropriate medical personnel respon sible for the subject’s welfare. Data generated for this study 
must be available for inspection on request to representatives of the FDA, other national or local 
health authorities, Sangamo, and the associated IRB/IEC. 
Release of research results or data that rev eal subject names or othe r identifiers, such as 
photographs, audio or videotapes, mu st be carried out in accordanc e with Department of Health 
and Human Services Standards for Privacy of  Individual Health information, 45 CFR 164.508. 
Written authorization must be obtained from the s ubject and IRB/IEC prior to  the release of such 
information. Identifiable subject data may not be  used for purposes of promoting the study drug. 
14.4 Reporting Obligations Sangam
o BioSciences, Inc., the sponsor of this I ND, is required to report  to the FDA annually on 
the status of the trial. Status reports must be filed by the Principal Investigator with their IRB on 
an annual basis. 
 
15. ADMINISTRATIVE CONSIDERATIONS 
15.1 Study Documentation 
The Investigator and study staff are responsible for 
maintaining a comprehensive and centralized 
filing system containing all st udy-related documentation. These files must be suitable for 
inspection by the Sponsor or the FDA at any time and should consist of the following elements: 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 45 of 70                                                                                   Version: January 30, 2014 a) Subject files containing the comple ted medical records, supporting source 
documentation, electronic case report forms and the IRB approved Informed 
Consent signed by subjects. 
b) Study files containing all version of  the IRB approved protocol with all 
amendments, IRB approved informed cons ent forms, copies of all pre-study 
documentation, Form FDA 1572 and all corre spondence to and from the IRB and 
the Sponsor. 
c) The investigator should ma intain a list of appropriatel y qualified persons who are 
delegated to perform significant study-relate d studies. In addition, the investigator 
should maintain a signature sheet to doc ument signatures and initials of all 
persons authorized to make entries and/or corrections on the source documents and electronic case report forms. 
15.2 Record Retention 
According to 21 CFR 312.62(c), the i nvestigator shall reta in records required to be m
aintained 
under this part for a period of 2 years following th e date a marketing application is approved for 
the drug for the indication for which it is being inve stigated. If no application is to be filed or if 
the application is not approved fo r such indication, the investigator shall retain  these records 
until 2 years after the investigation is discon tinued and the FDA is notified. These documents 
should be retained for a longer  period, however, if required by the applicable regulatory 
requirements or by an agreement with Sangamo BioSciences. It is the re sponsibility of Sangamo 
BioSciences to inform the investigator as to when  these documents no longer need to be retained. 
15.3 Case Report Forms The investigator is responsible f 
or the quality of the data reco rded on the case report form. The 
data recorded should be a complete and accurate account of the subject’s record collected during 
the study 
Clinical data will be recorded on case re port forms (CRFs) provided by Sangamo. All forms 
must be legible and complete. The investigator must review all entries for completeness and 
correctness. When changes or corrections are made on any case report form, an audit trail will be 
generated to record date and time when a change  is made, who made the change, and reason for 
the change as needed. The origin al entry should not be obscured. 
The investigator agrees to complete and sign  case report forms in a timely fashion, after 
completion of each subject, and make them ava ilable to the Sangamo study monitor for full 
inspection. In addition, all data queri es should be resolved promptly. 
15.4 Termination of the Study 
Sangam
o retains the right to terminate the stud y and remove all the study materials from the 
study site at any time. Specific instances that ma y precipitate such termination are as follows: 
• Completion of the study at an investigational site 
• Investigator withdrawal fr om participation in study 
• Termination of this study by Sangamo 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 46 of 70                                                                                   Version: January 30, 2014 15.5 Study Monitoring  
Sangamo BioSciences, as sponsor of this study, is responsible to regulatory authorities for 
ensuring the proper conduct of the study as regard s protocol adherence a nd validity of the data 
recorded on the case report forms presented to th e regulatory authorities.  Sangamo BioSciences 
has therefore assigned a clinical monitor and a medical monitor to this study. Their duties are to 
aid the investigator and, at the same time, Sanga mo BioSciences in the maintenance of complete, 
legible, well-organized, and easily retrievable data. In addition, a Sang amo BioSciences study 
monitor will ensure an understa nding of the protocol, reporting responsibilitie s, and the validity 
of the data.   
Individual study sites will be mon itored by a Sangamo representativ e at appropriate intervals to 
assure satisfactory consenting process, data reco rding, and protocol a dherence. In order to 
perform their roles well, the Sangamo BioSciences  monitors must be given direct access to 
primary subject data (source documents) that su pport data entered onto the case report forms. 
The investigator and staff are expected to  cooperate and provide all relevant study 
documentation in detail at each s ite visit on request for review. Each study center will also be 
routinely monitored by telephone to keep abreast of subject status and to answer questions. 
Regulatory authorities, the IRB, and/or the sp onsor’s clinical quali ty assurance group may 
request access to all source documents, case report forms, and other study documentation for on-
site audit, or inspection. Direct access to  these documents must be guaranteed by the 
investigator, who must pr ovide support at all times for these activities. 
The investigator or designated person should agr ee, as a minimum requirement, to record the 
following information in the subject notes: 
• Protocol identification number, br ief description or title of study 
• Date and statement that subject has given written informed consent 
• All study follow-up visit dates 
• AEs as described in Sections  10.0 and 11.0 of this protocol 
Entries in the subject notes must contain the signature or initials of the person making the entries. 
The clinical study monitor will perform source data verification at each monitoring visit. 
15.6 Publication Statement 
The results of
 this clinical trial may be used by Sangamo in registration documents for regulatory 
authorities in the U.S. or abroad, or for public dissemination in the form of papers, abstracts, 
posters, or other informational materials to be pr esented at scientific m eetings, or published in 
professional journals, or as a part of an academic thesis by an investigator. 
All proposed publications, papers, abstracts, or ot her written materials related to the study, or an 
outline of any proposed oral presentations, shall be submitted to Sangamo for approval at least 
45 days prior to (1) submission of such written materials for publication or  (2) any proposed oral 
disclosure to a third party. Sangamo shall have the right to review and comment on such written 
material or outline, and to confirm the accuracy of the data described therein by comparison with 
that collected during the course of this study. In the event that Sangamo determines that an 
enabling description of patentable subject matter is contained in su ch written material or outline, 
it shall notify the clinical site(s) within 1 mont h after receipt by Sangamo and Sangamo will have 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 47 of 70                                                                                   Version: January 30, 2014 an additional 90 days for review. 
In the event of publication using multi-center data, the number of subjects enrolled by each 
investigator will usually determine the order of  participation, unless otherwise agreed upon by 
the investigators and Sangamo. 
15.7 Study Funding 
The costs necessary to perform
 the study will be  agreed to by the investigator and/or the 
management of the study facility and will be docu mented in a separate financial agreement. All 
financial agreements will be signed by th e investigator and Sa ngamo BioSciences. 
 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 48 of 70                                                                                   Version: January 30, 2014 REFERENCES 
Aste-Amezaga, M et al. Quantative adenovirus neutralization assays based on the secreted 
alkaline phosphatase repo rter gene: application in epidemio logic studies and in the design of 
adenovector vaccines.  Human Gene Therapy 15: 293-304 (2004) 
Baker GL, Kahl LE, et al.: Malignancy following treatment of rheumatoid arthritis with 
cyclophosphamide. Long-term case-control follow-up study. Am J Med 83: 1-9, 1987. 
Bartlett JA, Miralles GD, et al.: Addition of cyclophosphamide to antiretroviral therapy does not 
diminish the cellular reservoir in HIV-infected  persons.  AIDS Rsrch and Human Retroviruses 
18:535-43, 2002 
Dudley ME, Wunderlich JR, et al: Adoptive cell transfer therapy following non-myeloablative 
but lymphodepleting chemotherapy for the treatmen t of patients with refractory metastatic 
melanoma. J Clin Onc 23:2346-57, 2005.  Dudley ME, Rosenberg SA: Adoptive cell-transfer for the treatment of patients with cancer. Nat 
Rev Cancer, 3:666-75, 2003. Hensley ML, et al.: American Society of C linical Oncology 2008 Clinic al Practice Guideline 
Update: Use of Chemotherapy and Radiation Therapy Protectants. J Clin Onc 27:127-145, 2009 
Kolb, JP, Poupon MF, et al.: Splenic modifica tions induced by cyclophosphamide in C3H/He, 
nude, and "B" mice." J Immunol 118: 1595-99, 1977. Laport GG, Levine BL, et al. Adoptive transfer of  costimulated T cells induces lymphocytosis in 
patients with relapsed/refractory non-H odgkin's lymphoma following CD34-selected 
hematopoietic cell transplantation. Blood 102: 2004-13, 2003. Lawrence J, Mayers DL, et al.: Structured tr eatment interruption in patients with multidrug 
resistant human immunodeficiency virus. New Engl J Med 349:837-46, 2003. 
LeBraz MLB, Fagard CF, et al.: Physical and psychological impacts of structured treatment 
interruptions. Poster presenta tion: The XIV International AI DS Conference: Abstract no. 
ThPpB2134. 
Martin F, Lauwerys B, et al: Side-effects of  intravenous cyclophosphamide pulse therapy. Lupus 
6:254-57, 1997. 
Nilsson, M et al. Developm ent of adenoviral vector system w ith adenovirus serotype 35 tropism; 
efficient transient gene transfer  into primary malignant hemat opoietic cells.  Journal Gene 
Medicine (6): 631-641(2004) 
Nordoy, T et al.: Humoral immunity to viral a nd bacterial antigens in  lymphoma patients 4-10 
years after high-dose therapy with ABMT. Serological responses to revaccination according to 
EBMT guidelines. Bone Marrow Transplant. 28:681-87, 2001. 
Oxenius A, Price DA, et al.: Stimulation of HIV-specific cellular immunity by structured 
treatment interruption fails to enhance viral contro l in chronic HIV infection. Proc Natl Acad Sci 
USA 99:13747-52, 2002. Patton, NI: Treatment Interruption strategies: how great are the risks? Curr Opin Infect Dis 
21:25-30, 2008. 
Sangamo BioSciences, Inc.  
Protocol SB-728-1101                                                                                                                 Confidential 
Page 49 of 70                                                                                   Version: January 30, 2014 Perez et al.: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-
finger nucleases.  Nature Biotechnology  26, 808 - 816 (2008)  
Porter DL, Levine BL, et al.:  A phase I trial of donor lymphocyte infusions expanded and 
activated ex-vivo via CD3/CD28 co-stimulation. Blood 107: 1325-31, 2006. 
Porter DL, Levine BL, et al.: Chimeric antig en receptor-modified T cells in chronic lymphoid 
leukemia. New Engl J Med 365:725-33, 2011. 
Rapoport AP, Levine BL, et al.: Molecular remission of CML after autotransplantation followed 
by adoptive transfer of costimulated autol ogous T cells. Bone Marrow Transplant. 33:53-60, 
2004. 
Rapoport AP, Stadtmauer EA, et al.: Restoration of immunity in lymphopenic individuals with 
cancer by vaccination and adoptive T-cel l transfer. Nat Med 11: 1230-1237, 2005. 
Rapoport AP, Aqui NA, et al.: Combination immunotherapy using adoptive T-cell transfer and 
tumor antigen vaccination based on hTERT and su rvivin following ASCT for myeloma. Blood 
117: 788-97, 2011. Small, E.J et al. A phase I tria l of intravenous CG7870, a replicatio n-selective, prostate-specific 
antigen-targeted oncolytic adenovirus, for th e treatment of hormone-refractory, metastatic 
prostate cancer. Molecular Therapy 14, 107-117 (2006b) 
Stadtmauer E A, Vogl DT, et al.: Transfer  of Influenza Vaccine-Primed Co-stimulated 
Autologous T-Cells after Stem Cell Transp lantation for Multiple Myeloma Leads to 
Reconstitution of Influenza Imm unity: Results of a Randomized Clinical Trial. Blood 117: 63-
71, 2011. Taylor S, Boffito M, et al.: Stoppin g antiretroviral therapy. AIDS 21:1673-82, 2007. 
Van Lunzen J, Glaunsinger T, et al.: Transfer  of autologous gene-modified T cells in HIV-
infected patients with advanced immunodeficiency  and drug-resistant virus. Molecular Therapy 
15:1024-33, 2007. Willers JM, Sluis E: The influence of cyclophosphamide on antibody formation in the mouse." 
Ann Immunol (Paris) 126: 267-79, 1975. 
  
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 50 of 70                                                                                   Version: January 30, 2014 APPENDIX 1:  SCHEDULE OF EVENTS  
Procedure   Screen 
 
Pre‐Leukapheresis  
(1 wk prior to 
leukapheresis)  
Leukapheresisa Baseline 
for 
Research 
Blood 
(between  
Leuk and 
CTX) Baseline  
(~1 wk 
prior to 
CTX) CTX  Day 0  Day 
1 Day 5 
(‐1 day) 
Cohorts 4 
& 5 only Wk 1 
(+2 
days) Day 12 
(‐1 day) 
Cohorts 
4 & 5 
only Wk 2 
(+2 
days) Wk 3 
(+2 
days) Wk 4 
(+2 
days) Wk 6 
(+3 
days) 
‐‐‐‐‐‐‐‐‐ 
Start TI Wk 8 
(+3 days) Wk 10 
(+3 days) Wk 12 
(+3 
days) Wk 14 
(+3 days) Wk 18 
(+1 wk) Wk 22  
(+1 wk)  
_____ 
Evaluate 
TIm M 7, M 8,  
M 10, M 12 
(+1 wk) 
Inclusion Exclusion  / 
Informed   Consentb X                                          
Medical History  X                                          
Physical Exam  X                                       X 
M12 only 
Vital Signsc        X  X  X            X            X X 
M8 only 
12‐lead ECG  X                                           
Leukapheresis       X                                      
Cyclophosphamide  
Administration          Xd                             
SB‐728‐T infusion              Xe                               
Adverse  events      X    X  X  X  X    X    X  X  X  X  X  X  X  X  X  X  X 
Concomitant  medications   X    
  X  X  X    X  X  X  X  X  X  X  X  X  X  X  X 
Hepatitis B and Cf X                                          
Pregnancy  Testg  X      X                                  
Chemistry   X  Xh   
X  X  X  X  
X  
  X  
 X  X  
 X  
 X  X X 
M7, M10, M12 
only 
CBC w diff / platelets(ANC  
at Screen through Week 
4) X  X  X 
(CBC 
w/diff 
only) X  Xi  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X 
Urinalysis   X      X  X  X  X  X      X               X 
M7, M12 only 
CD4+ T‐cell counts  X      X  X  X  X  X    X    X  X  X  Xi  Xi  Xi  Xi  Xi  Xi  Xi  X 
HIV‐1 RNA (Viral Load)  X        X          X    X  X  X  Xj  Xj  Xj  Xj  Xj  Xj  Xj  X 
CCR5 SNP  CEL‐1 assay  X                                          
Ad and SB‐728 
immunogenicity  X      Xk        X      X      X       X 
M7, M12 only 
Pentamer         
Xk      X  
X  
X  X  X  X  X  X  X  X  X  X X 
Month 8 and 
12 only 
HIV‐1 Coreceptor  and 
resistance  test X                      Xm   
Research Blood  X      X  Xl    X  X       X      X        X    X  X 
Upon request of sponsor: Additional  80 mL research blood collection,  CBC with differential,  and CD4+ T‐cell Count:  One to 2 times during the study. If subject agrees to participate  in the optional leukapheresis  procedure,  this additional  blood collection  will not be 
performed.  
 
 a If second  leukapheresis  is required, it must be > 3 weeks after the first leukapheresis.   
b Inform  subjects of Long‐term, Follow‐up study 
c Ht and wt at BL,  Vital signs on CTX and Day 0 (temp., pulse,  BP) and on Wks 6, 22 and M8 and M12 (temp, pulse, BP and weight) 
d Cyclophosphamide  should be administered  up to 3 days prior to the SB‐728‐T infusion. Refer to Protocol Sections 6.5.1  and 8.2 and the Study Reference  
Manual for further details 
e Refer to Protocol Sections 6.5.2  and 8.1 and the Study Reference  Manual for further details 
f Not required if negative results  within 60 days of screening  visit 
g Serum pregnancy  test at Screen and urine pregnancy  test at Baseline  
h Electrolytes  (Na,  K, C02, Cl), calcium, liver function tests (albumin,  total protein, alkaline phosphatase,  AST, ALT, total bilirubin)iCD4 test will be repeated every 2 weeks for 3 consecutive  measurements  for values <500 cells/µL 
j HIV‐1 RNA test will be repeated every  2 weeks for 3 consecutive  measurements  for values >100,000  
copies/mL   
k May  be performed  up to 4 weeks prior to the SB‐728‐T infusion, Day 0.  
lResearch blood may be drawn on day of and prior to cyclophosphamide  infusion. 
m HIV‐1 coreceptor  and resistance  testing will be performed  once if HIV RNA exceeds 1,000 copies/mL  
during TI. Refer to protocol sections 6.5, 8.3, and 9.3
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 51 of 70                                                                                   Version: January 30, 2014 
 APPENDIX II: DIVISION OF AIDS TABLE FOR GRADING THE SEVERITY OF 
ADULT AND PEDIATRIC ADVERSE EVENTS 
 
Version 1.0, December, 2004; clarification August 2009 
 
The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (“DAIDS AE Grading Table”) is a descriptive terminology which can be utilized for Adverse 
Event (AE) reporting. A grading (severity)  scale is provided for each AE term. 
 
This clarification of the DAIDS Table for Grad ing the Severity of A dult and Pediatric AE’s 
provides additional explanation of the DAIDS AE Grading Table and clarifies some of the parameters.  
 
I. INSTRUCTIONS AND CLARIFICATIONS  
Grading Adult and Pediatric AEs
 
The DAIDS AE Grading Table includes parameters  for grading both Adult and Pediatric AEs.  
When a single set of parameters is not appropr iate for grading specifi c types of AEs for both 
Adult and Pediatric populations, separate sets  of parameters for Adult and/or Pediatric 
populations (with specified respec tive age ranges) are given in th e Table.  If there is no 
distinction in the Table between Adult and Pediatric values for a type of AE, then the single set 
of parameters listed is to be used for grading th e severity of both Adult and Pediatric events of 
that type.   
Note: In the classification of advers e events, the term “severe” is not  the same as 
“serious.” Severity is an indication of the intensity  of a specific event (as in mild, 
moderate, or severe chest pain).  The term  “serious” relates to a participant/event 
outcome or action criteria , usually associated with events that pose a threat to a 
participant’s life or functioning.  
 
Addenda 1-3 Grading Tables for Microbicide Studies  
For protocols involving topical a pplication of products to the fe male genital tract, male genital 
area or rectum, strong considera tion should be given to using Appendices I-III as the primary 
grading scales for these areas. The protocol would need to specifically state that one or more of 
the Appendices would be primary (and thus take precedence over the main Grading Table) for items that are listed in both the Appendix and the main Grading Table. 
Addendum 1 - Female Genital Grading Ta ble for Use in Microbicide Studies - PDF
 
Addendum 2 - Male Genital Grading Table for Use in Microbicide Studies - PDF  
Addendum 3 - Rectal Grad ing Table for Use in Microbicide Studies - PDF  
 Grade 5
 
For any AE where the outcome is death, the sever ity of the AE is classified as Grade 5.  
 Estimating Severity Grade for Parameters Not Identified in the Table
 
In order to grade a c linical AE that is not  identified in the DAIDS AE grading table, use the 
category “Estimating Severity Grade” located on Page 3.  
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 52 of 70                                                                                   Version: January 30, 2014 
  
Determining Severity Grade for Parameters “Between Grades”  
If the severity of a clinical AE  could fall under either one of two grades (e.g., the severity of an 
AE could be either Grade 2 or Grade 3), select  the higher of the two gr ades for the AE. If a 
laboratory value that is graded as a multiple of the ULN or LLN falls between two grades, select 
the higher of the two grades for the AE. For example, Grade 1 is 2.5 x ULN and Grade 2 is 2.6 x ULN for a parameter. If the lab value is 2.53 x ULN (which is between the two grades), the 
severity of this AE would be Gr ade 2, the higher of the two grades. 
 
Values Below Grade 1
 
Any laboratory value that is be tween either the LLN or ULN a nd Grade 1 should not be graded. 
 
Determining Severity Grade when Local Labor atory Normal Values Overlap with Grade 1 
Ranges  
In these situations, the severity  grading is based on the ranges in the DAIDS AE Grading Table, 
even when there is a reference to the local lab LLN.  For example: Phosphate, Serum, Low, Adult and Pediatric > 14 years Grade 1 range is 2.50 
mg/dL - < LLN. A particular la boratory’s normal range for Phos phate is 2.1 – 3.8 mg/dL. A 
participant’s actual lab value is 2.5.   In this case, the value of 2.5 exceeds the LLN for the local 
lab, but will be graded as Grade 1 per DAIDS AE Grading Table. 
 
II. DEFINITIONS OF TERMS USED IN THE TABLE: 
 
Basic Self-care Functions Adult
 
Activities such as bathing, dressing, toileting, 
transfer/movement, continence, and feeding. Young Children
 
Activities that are ag e and culturally appropriate (e.g., feeding 
self with culturally appropriate eating implement). 
LLN Lower limit of normal 
 
Medical Intervention Use of pharmacologic or biologic agent(s) for treatment of an 
AE. 
NA Not Applicable 
Operative Intervention Surgical OR ot her invasive mechanical procedures. 
ULN Upper limit of normal 
Usual Social & Functional Activities Adult
 
Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc. Young Children
 
Activities that are ag e and culturally appropriate (e.g., social 
interactions, play activitie s, learning tasks, etc.). 
 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 53 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
ESTIMATING SEVERITY GRADE 
Clinical adverse event NOT identified 
elsewhere in this 
DAIDS AE Grading 
Table  Symptoms causing no 
or minimal 
interference with 
usual social & 
functional activities Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities Symptoms causing 
inability to perform usual 
social & functional 
activities Symptoms causing inability to perform basic 
self-care functions OR 
Medical or operative 
intervention indicated to 
prevent permanent 
impairment, persistent 
disability, or death  
SYSTEMIC 
Acute systemic 
allergic reaction  Localized urticaria (wheals) with no 
medical intervention 
indicated Localized urticaria with medical intervention 
indicated OR Mild 
angioedema with no 
medical intervention 
indicated  Generalized urticaria OR Angioedema with 
medical intervention 
indicated OR 
Symptomatic mild 
bronchospasm Acute anaphylaxis OR Life-threatening 
bronchospasm OR 
laryngeal edema 
Chills Symptoms causing no 
or minimal 
interference with 
usual social & functional activities Symptoms causing greater than minimal 
interference with usual 
social & functional activities  Symptoms causing inability to perform usual 
social & functional 
activities NA 
Fatigue 
Malaise Symptoms causing no 
or minimal 
interference with 
usual social & 
functional activities  Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities  Symptoms causing 
inability to perform usual 
social & functional 
activities  Incapacitating fatigue/ malaise symptoms 
causing inability to 
perform basic self-care 
functions  
Fever (nonaxillary)  37.7 – 38.6 °C 38.7 – 39.3 °C 39.4 – 40.5 °C > 40.5°C  
Pain (indicate body 
site) 
DO NOT use for pain 
due to injection (See 
Injection Site 
Reactions: Injection 
site pain) 
See also Headache, 
Arthralgia, and 
Myalgia Pain causing no or 
minimal interference with usual social & 
functional activities Pain causing greater 
than minimal interference with usual 
social & functional 
activities  Pain causing inability to perform usual social & functional activities Disabling pain causing inability to perform basic self-care functions OR 
Hospitalization (other 
than emergency room 
visit) indicated 
 
Basic Self-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 54 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Unintentional weight 
loss NA 5 – 9% loss in body 
weight from baseline 10 – 19% loss in body weight from baseline ≥ 20% loss in body 
weight from baseline OR  Aggressive intervention 
indicated [e.g., tube 
feeding or total parenteral nutrition 
(TPN)] 
INFECTION 
Infection (any other 
than HIV infection) Localized, no systemic antimicrobial 
treatment indicated 
AND Symptoms 
causing no or minimal 
interference with 
usual social & 
functional activities Systemic antimicrobial treatment indicated 
OR Symptoms 
causing greater than 
minimal interference 
with usual social & 
functional activities Systemic antimicrobial 
treatment indicated 
AND Symptoms causing 
inability to perform usual 
social & functional 
activities OR Operative 
intervention (other than 
simple incision and 
drainage) indicated Life-threatening 
consequences (e.g., 
septic shock) 
INJECTION SITE REACTIONS 
Injection site pain 
(pain without touching) 
Or 
Tenderness (pain 
when area is touched)  Pain/tenderness 
causing no or minimal 
limitation of use of 
limb Pain/tenderness limiting use of limb OR 
Pain/tenderness 
causing greater than 
minimal interference 
with usual social & 
functional activities 
 Pain/tenderness 
causing inability to 
perform usual social & 
functional activities 
 Pain/tenderness causing 
inability to perform basic 
self-care function OR 
Hospitalization (other 
than emergency room 
visit) indicated for 
management of 
pain/tenderness 
Injection site reaction (localized) 
Adult > 15 years  
 Erythema OR Induration of 5x5 cm – 9x9 cm 
(or 25 cm
2 – 81cm2) Erythema OR 
Induration OR  Edema 
> 9 cm any diameter 
(or > 81 cm2) Ulceration OR 
Secondary infection OR Phlebitis OR Sterile 
abscess OR Drainage Necrosis (involving 
dermis and deeper tissue) 
 
Pediatric ≤ 15 years  Erythema OR 
Induration OR Edema 
present but ≤ 2.5 cm 
diameter Erythema OR 
Induration OR Edema 
> 2.5 cm diameter but 
< 50% surface area of 
the extremity segment 
(e.g., upper arm/thigh) Erythema OR Induration OR Edema involving  
≥ 50% surface area of 
the extremity segment 
(e.g., upper arm/thigh) OR Ulceration OR 
Secondary infection OR 
Phlebitis OR Sterile 
abscess OR Drainage Necrosis (involving 
dermis and deeper 
tissue) 
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 55 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Pruritis associated 
with injection  
See also Skin: Pruritis 
(itching - no skin 
lesions) Itching localized to 
injection site AND 
Relieved 
spontaneously or with 
< 48 hours treatment  Itching beyond the 
injection site but not 
generalized OR 
Itching localized to 
injection site requiring 
≥ 48 hours treatment  Generalized itching 
causing inability to 
perform usual social & 
functional activities NA 
SKIN – DERMATOLOGICAL 
Alopecia Thinning detectable 
by study participant (or by caregiver for 
young children and 
disabled adults) Thinning or patchy 
hair loss detectable by 
health care provider Complete hair loss NA 
Cutaneous reaction – rash Localized macular rash  Diffuse macular, maculopapular, or 
morbilliform rash OR 
Target lesions  Diffuse macular, maculopapular, or 
morbilliform rash with 
vesicles or limited 
number of bullae OR 
Superficial ulcerations 
of mucous membrane 
limited to one site Extensive or generalized bullous lesions OR 
Stevens-Johnson 
syndrome OR Ulceration 
of mucous membrane 
involving two or more 
distinct mucosal sites 
OR Toxic epidermal 
necrolysis (TEN) 
Hyperpigmentation Slight or localized Marked or generalized NA NA 
Hypopigmentation Slight or localized  Marked or generalized NA NA 
Pruritis (itching – no skin lesions)  
(See also Injection 
Site Reactions: 
Pruritis associated 
with injection) Itching causing no or minimal interference 
with usual social & 
functional activities Itching causing greater than minimal 
interference with usual 
social & functional 
activities Itching causing inability 
to perform usual social 
& functional activities  NA 
 
CARDIOVASCULAR 
Cardiac arrhythmia 
(general) 
(By ECG or physical 
exam) Asymptomatic AND No intervention 
indicated Asymptomatic AND 
Non-urgent medical 
intervention indicated Symptomatic, non-life-
threatening AND Non-
urgent medical 
intervention indicated  Life-threatening arrhythmia OR Urgent 
intervention indicated 
Cardiac-
ischemia/infarction NA NA Symptomatic ischemia 
(stable angina) OR 
Testing consistent with 
ischemia  Unstable angina OR Acute myocardial 
infarction 
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 56 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Hemorrhage (significant 
acute blood loss) NA Symptomatic AND No 
transfusion indicated  Symptomatic AND 
Transfusion of ≤ 2 units 
packed RBCs (for children 
≤ 10 cc/kg) indicated  Life-threatening 
hypotension OR Transfusion of > 2 units 
packed RBCs (for children > 
10 cc/kg) indicated  
Hypertension 
Adult > 17 years 
(with repeat testing at 
same visit) 140 – 159 mmHg 
systolic 
OR 
90 – 99 mmHg diastolic  160 – 179 mmHg systolic OR 
100 – 109 mmHg 
diastolic ≥ 180 mmHg systolic 
OR 
≥ 110 mmHg diastolic 
 Life-threatening 
consequences (e.g., 
malignant hypertension) 
OR Hospitalization indicated (other than 
emergency room visit)  
Correction : in Grade 2 to 160 - 179 from > 160-179 (systolic) and to  ≥ 100 -109 from > 100-109 (diastolic) and in Grade 3 to  ≥ 180 from > 180 
(systolic) and to  ≥ 110  from > 110 (diastolic). 
Pediatric ≤  17 years  
(with repeat testing at 
same visit) 
 NA 91st –  94th percentile 
adjusted for age, height, 
and gender (systolic and/or diastolic) ≥ 95
th percentile adjusted 
for age, height, and gender (systolic and/or diastolic) Life-threatening 
consequences (e.g., 
malignant hypertension) OR Hospitalization 
indicated (other than 
emergency room visit) 
Hypotension NA Symptomatic, 
corrected with oral 
fluid replacement Symptomatic, IV fluids 
indicated Shock requiring use of vasopressors or 
mechanical assistance 
to maintain blood 
pressure 
Pericardial effusion Asymptomatic, small 
effusion requiring no 
intervention  Asymptomatic, 
moderate or larger 
effusion requiring no 
intervention  Effusion with non-life threatening physiologic 
consequences OR 
Effusion with non-urgent 
intervention indicated  Life-threatening 
consequences (e.g., 
tamponade) OR Urgent 
intervention indicated  
Prolonged PR interval 
Adult > 16 years PR interval  0.21 – 0.25 sec PR interval > 0.25 sec Type II 2
nd degree AV 
block OR Ventricular 
pause > 3.0 sec Complete AV block 
Pediatric ≤ 16 years 1st degree AV block 
(PR > normal for age and rate) Type I 2nd degree AV 
block  Type II 2nd degree AV 
block  Complete AV block 
Basic Self-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activi ties, learning tasks, etc.).  
 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 57 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Prolonged QTc 
Adult > 16 years 
 Asymptomatic, QTc 
interval 0.45 – 0.47 
sec OR Increase 
interval < 0.03 sec 
above baseline Asymptomatic, QTc 
interval 0.48 – 0.49 
sec OR Increase in 
interval 0.03 – 0.05 
sec above baseline Asymptomatic, QTc 
interval ≥ 0.50 sec OR 
Increase in interval  ≥ 0.06 sec above baseline Life-threatening 
consequences, e.g. 
Torsade de pointes or 
other associated serious ventricular dysrhythmia 
Pediatric ≤ 16 years Asymptomatic, QTc 
interval 0.450 –  
0.464 sec  Asymptomatic, QTc 
interval 0.465 –  
0.479 sec  Asymptomatic, QTc 
interval ≥ 0.480 sec  Life-threatening 
consequences, e.g.  Torsade de pointes  or other associated serious ventricular dysrhythmia 
Thrombosis/embolism NA Deep vein thrombosis 
AND No intervention 
indicated (e.g., 
anticoagulation, lysis 
filter, invasive 
procedure)  Deep vein thrombosis AND Intervention 
indicated (e.g., 
anticoagulation, lysis 
filter, invasive 
procedure)  Embolic event (e.g., pulmonary embolism, 
life-threatening 
thrombus)  
Vasovagal episode (associated with a 
procedure of any kind) Present without loss 
of consciousness  Present with transient 
loss of consciousness NA  NA 
Ventricular 
dysfunction 
(congestive heart 
failure) NA Asymptomatic 
diagnostic finding AND intervention indicated New onset with symptoms OR Worsening symptomatic congestive heart failure Life-threatening congestive heart failure 
GASTROINTESTINAL 
Anorexia Loss of appetite 
without decreased 
oral intake Loss of appetite 
associated with 
decreased oral intake 
without significant weight loss Loss of appetite associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated [e.g., tube feeding or total parenteral nutrition (TPN)] 
Comment:  Please note that, while the grading scale provided for Unintentional Weight Loss may be used as a guideline  when 
grading anorexia, this is not a requirement and should not be used as a substitute for clinical judgment.  
Ascites Asymptomatic Symptomatic AND 
Intervention indicated 
(e.g., diuretics or 
therapeutic 
paracentesis) Symptomatic despite 
intervention Life-threatening consequences 
 
Basic Self-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 58 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Cholecystitis NA Symptomatic AND 
Medical intervention indicated Radiologic, endoscopic, or operative intervention indicated Life-threatening consequences (e.g., sepsis or perforation)  
Constipation  NA Persistent constipation 
requiring regular use 
of dietary 
modifications, 
laxatives, or enemas  Obstipation with manual 
evacuation indicated  Life-threatening consequences (e.g., 
obstruction)  
Diarrhea 
Adult and Pediatric 
≥ 1 year  Transient or 
intermittent episodes 
of unformed stools 
OR Increase of ≤  3 
stools over baseline per 24-hour period Persistent episodes of unformed to watery 
stools OR Increase of 
4 – 6 stools over 
baseline per 24-hour 
period Bloody diarrhea OR Increase of ≥ 7 stools 
per 24-hour period OR IV fluid replacement 
indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Pediatric < 1 year  Liquid stools (more 
unformed than usual) 
but usual number of 
stools Liquid stools with increased number of 
stools OR Mild 
dehydration Liquid stools with moderate dehydration Liquid stools resulting in severe dehydration with 
aggressive rehydration 
indicated OR 
Hypotensive shock 
Dysphagia-Odynophagia  Symptomatic but able to eat usual diet Symptoms causing altered dietary intake 
without medical 
intervention indicated Symptoms causing severely altered dietary 
intake with medical 
intervention indicated Life-threatening reduction in oral intake 
Mucositis/stomatitis  (clinical exam
) 
Indicate site (e.g., larynx, oral) 
See Genitourinary for 
Vulvovaginitis  
See also Dysphagia-
Odynophagia and 
Proctitis Erythema of the 
mucosa Patchy pseudomembranes or 
ulcerations  Confluent 
pseudomembranes or 
ulcerations OR Mucosal 
bleeding with minor 
trauma Tissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding OR 
Life-threatening 
consequences (e.g., 
aspiration, choking) 
Nausea  Transient (< 24 hours) 
or intermittent nausea with no or minimal 
interference with oral 
intake Persistent nausea 
resulting in decreased 
oral intake for 24 – 48 
hours Persistent nausea resulting in minimal oral 
intake for > 48 hours 
OR Aggressive 
rehydration indicated 
(e.g., IV fluids) Life-threatening consequences (e.g., 
hypotensive shock) 
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 59 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated (other than 
emergency room visit) Symptomatic AND Hospitalization indicated 
(other than emergency 
room visit) Life-threatening consequences (e.g., 
circulatory failure, 
hemorrhage, sepsis) 
Proctitis (functional-  
symptomatic ) 
Also see 
Mucositis/stomatitis  
for clinical exam Rectal discomfort 
AND No intervention 
indicated Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Medical intervention indicated  Symptoms causing 
inability to perform usual 
social & functional 
activities OR Operative 
intervention indicated  Life-threatening 
consequences (e.g., 
perforation) 
 
Vomiting Transient or 
intermittent vomiting 
with no or minimal 
interference with oral 
intake Frequent episodes of 
vomiting with no or 
mild dehydration Persistent vomiting 
resulting in orthostatic 
hypotension OR 
Aggressive rehydration 
indicated (e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
NEUROLOGIC 
Alteration in 
personality-behavior 
or in mood (e.g., 
agitation, anxiety, 
depression, mania, 
psychosis) Alteration causing no or minimal 
interference with 
usual social & 
functional activities  Alteration causing 
greater than minimal 
interference with usual 
social & functional 
activities  Alteration causing 
inability to perform usual 
social & functional 
activities  Behavior potentially harmful to self or others 
(e.g., suicidal and 
homicidal ideation or 
attempt, acute 
psychosis) OR Causing 
inability to perform basic 
self-care functions  
Altered Mental Status  
For Dementia, see 
Cognitive and 
behavioral/attentional 
disturbance (including 
dementia and 
attention deficit 
disorder) Changes causing no or minimal 
interference with 
usual social & 
functional activities Mild lethargy or 
somnolence causing 
greater than minimal 
interference with usual 
social & functional 
activities Confusion, memory impairment, lethargy, or 
somnolence causing 
inability to perform usual 
social & functional 
activities Delirium OR obtundation, OR coma 
Ataxia  Asymptomatic ataxia 
detectable on exam OR Minimal ataxia 
causing no or minimal 
interference with 
usual social & 
functional activities Symptomatic ataxia 
causing greater than 
minimal interference 
with usual social & 
functional activities Symptomatic ataxia 
causing inability to 
perform usual social & 
functional activities  Disabling ataxia causing inability to perform basic 
self-care functions 
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 60 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Cognitive and 
behavioral/attentional 
disturbance (including 
dementia and 
attention deficit 
disorder)  Disability causing no or minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources not 
indicated Disability causing greater than minimal 
interference with usual 
social & functional 
activities OR 
Specialized resources 
on part-time basis 
indicated Disability causing inability to perform usual 
social & functional 
activities OR 
Specialized resources 
on a full-time basis 
indicated Disability causing 
inability to perform basic 
self-care functions OR 
Institutionalization 
indicated 
CNS ischemia 
(acute) NA NA Transient ischemic 
attack Cerebral vascular accident (CVA, stroke) 
with neurological deficit  
Developmental delay 
– Pediatric ≤ 16 
years  Mild developmental 
delay, either motor or 
cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting  Moderate 
developmental delay,  
either motor or 
cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting  Severe developmental delay, either motor or 
cognitive, as determined 
by comparison with a 
developmental 
screening tool 
appropriate for the 
setting  Developmental regression, either motor 
or cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting 
Headache  Symptoms causing no 
or minimal interference with 
usual social & 
functional activities Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities  Symptoms causing 
inability to perform usual 
social & functional 
activities  Symptoms causing inability to perform basic 
self-care functions OR 
Hospitalization indicated 
(other than emergency 
room visit) OR 
Headache with 
significant impairment of 
alertness or other 
neurologic function  
Insomnia NA Difficulty sleeping 
causing greater than minimal interference 
with usual social & 
functional activities Difficulty sleeping causing inability to perform usual social & 
functional activities Disabling insomnia 
causing inability to perform basic self-care 
functions 
Neuromuscular 
weakness  
(including myopathy & 
neuropathy)  Asymptomatic with decreased strength 
on exam OR Minimal 
muscle weakness 
causing no or minimal 
interference with 
usual social & 
functional activities  Muscle weakness causing greater than 
minimal interference 
with usual social & 
functional activities  Muscle weakness 
causing inability to 
perform usual social & 
functional activities  Disabling muscle weakness causing 
inability to perform basic 
self-care functions OR 
Respiratory muscle 
weakness impairing 
ventilation  
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 61 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Neurosensory 
alteration (including 
paresthesia and 
painful neuropathy) Asymptomatic with sensory alteration on 
exam or minimal 
paresthesia causing 
no or minimal 
interference with 
usual social & 
functional activities  Sensory alteration or paresthesia causing 
greater than minimal 
interference with usual 
social & functional 
activities  Sensory alteration or paresthesia causing 
inability to perform usual 
social & functional 
activities Disabling sensory 
alteration or paresthesia 
causing inability to 
perform basic self-care 
functions 
 
Seizure: (new onset )  
– Adult ≥ 18 years  
See also Seizure: 
(known pre-existing 
seizure disorder) NA 1 seizure  2 – 4 seizures  Seizures of any kind 
which are prolonged, 
repetitive (e.g., status 
epilepticus), or difficult to 
control (e.g., refractory 
epilepsy) 
Seizure: (known pre-
existing seizure 
disorder )  
– Adult ≥ 18 years  
For worsening of existing epilepsy the 
grades should be 
based on an increase 
from previous level of 
control to any of these 
levels. NA Increased frequency 
of pre-existing seizures (non-
repetitive) without 
change in seizure 
character OR 
Infrequent break-
through seizures while 
on stable medication 
in a previously 
controlled seizure 
disorder Change in seizure character from baseline 
either in duration or 
quality (e.g., severity or  
focality)  Seizures of any kind 
which are prolonged, 
repetitive (e.g., status 
epilepticus), or difficult to 
control (e.g., refractory 
epilepsy) 
Seizure  
– Pediatric < 18 
years Seizure, generalized 
onset with or without 
secondary 
generalization, lasting 
< 5 minutes with < 24 
hours post ictal state Seizure, generalized onset with or without 
secondary 
generalization, lasting 
5 – 20 minutes with  
< 24 hours post ictal 
state Seizure, generalized 
onset with or without 
secondary 
generalization, lasting  
> 20 minutes  Seizure, generalized 
onset with or without 
secondary 
generalization, requiring 
intubation and sedation 
Syncope (not associated with a 
procedure) NA Present NA NA 
Vertigo Vertigo causing no or 
minimal interference 
with usual social & 
functional activities Vertigo causing greater than minimal 
interference with usual 
social & functional 
activities  Vertigo causing inability 
to perform usual social 
& functional activities Disabling vertigo 
causing inability to 
perform basic self-care 
functions 
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and cult urally appropriate  (e.g., social 
interactions, play activities, learning tasks, etc.). 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 62 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
RESPIRATORY 
Bronchospasm (acute) FEV1 or peak flow 
reduced to  
70 – 80%  FEV1 or peak flow  
50 – 69%  FEV1 or peak flow  25 – 49%  Cyanosis OR FEV1 or 
peak flow < 25% OR 
Intubation  
Dyspnea or respiratory distress 
Adult ≥ 14 years  Dyspnea on exertion with no or minimal 
interference with 
usual social & functional activities  Dyspnea on exertion causing greater than 
minimal interference 
with usual social & functional activities  Dyspnea at rest causing inability to perform usual 
social & functional 
activities  Respiratory failure with ventilatory support 
indicated 
Pediatric < 14 years  Wheezing OR minimal increase in 
respiratory rate for 
age Nasal flaring OR Intercostal retractions 
OR Pulse oximetry 90 
– 95% Dyspnea at rest causing inability to perform usual 
social & functional 
activities OR Pulse 
oximetry < 90% Respiratory failure with 
ventilatory support 
indicated 
MUSCULOSKELETAL 
Arthralgia 
See also Arthritis Joint pain causing no 
or minimal 
interference with 
usual social & 
functional activities Joint pain causing 
greater than minimal 
interference with usual 
social & functional 
activities Joint pain causing 
inability to perform usual 
social & functional 
activities Disabling joint pain causing inability to 
perform basic self-care 
functions 
Arthritis 
See also Arthralgia Stiffness or joint 
swelling causing no or 
minimal interference 
with usual social & 
functional activities Stiffness or joint 
swelling causing 
greater than minimal 
interference with usual 
social & functional 
activities Stiffness or joint swelling causing 
inability to perform usual 
social & functional 
activities Disabling joint stiffness 
or swelling causing 
inability to perform basic 
self-care functions  
Bone Mineral Loss 
Adult ≥ 21 years  BMD t-score  
-2.5 to -1.0  BMD t-score < -2.5 Pa thological fracture 
(including loss of 
vertebral height) Pathologic fracture 
causing life-threatening 
consequences  
Pediatric < 21 years BMD z-score  
-2.5 to -1.0 BMD z-score < -2.5 Pathological fracture 
(including loss of 
vertebral height) Pathologic fracture 
causing life-threatening 
consequences  
Myalgia (non-injection site
) Muscle pain causing no or minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
greater than minimal 
interference with usual 
social & functional 
activities Muscle pain causing 
inability to perform usual 
social & functional 
activities Disabling muscle pain causing inability to 
perform basic self-care 
functions 
Basic Self-care Functions – Adult : Activities such as bathing, dressing, toile ting, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appropriate (e.g., feeding self with culturally appropriate 
eating implement). 
Usual Social & Functional Activities – Adult : Adaptive tasks and desirable activities, such as going to work, shopping,  cooking, use of 
transportation, pursuing a hobby, etc. Usual Social & Functional Activities – Young Children : Activities that are age and culturally appr opriate (e.g., social interactions, play 
activities, learning tasks, etc.).
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 63 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Osteonecrosis NA Asymptomatic with 
radiographic findings AND No operative 
intervention indicated Symptomatic bone pain with radiographic 
findings OR Operative 
intervention indicated Disabling bone pain with radiographic findings 
causing inability to 
perform basic self-care 
functions 
GENITOURINARY 
Cervicitis  (symptoms
) 
(For use in studies 
evaluating topical  
study agents)  
For other cervicitis see 
Infection: Infection 
(any other than HIV 
infection)  Symptoms causing no or minimal 
interference with usual social & 
functional activities  Symptoms causing greater than minimal 
interference with usual social & functional 
activities  Symptoms causing inability to perform usual 
social & functional activities  
 Symptoms causing 
inability to perform basic 
self-care functions  
Cervicitis  
(clinical exam ) 
(For use in studies evaluating topical  
study agents)  
For other cervicitis see 
Infection: Infection 
(any other than HIV 
infection)  Minimal cervical 
abnormalities on 
examination 
(erythema, 
mucopurulent 
discharge, or friability) 
OR Epithelial 
disruption  
< 25% of total surface Moderate cervical 
abnormalities on 
examination 
(erythema, 
mucopurulent 
discharge, or friability) 
OR Epithelial 
disruption of 25 – 49% 
total surface Severe cervical 
abnormalities on 
examination (erythema, 
mucopurulent 
discharge, or friability) 
OR Epithelial disruption  
50 – 75% total surface Epithelial disruption  
> 75% total surface 
Inter-menstrual 
bleeding (IMB) Spotting observed by participant OR 
Minimal blood 
observed during 
clinical or colposcopic 
examination Inter-menstrual bleeding not greater in 
duration or amount 
than usual menstrual 
cycle Inter-menstrual bleeding 
greater in duration or 
amount than usual 
menstrual cycle Hemorrhage with life-threatening hypotension 
OR Operative 
intervention indicated 
Urinary tract obstruction (e.g., 
stone) NA Signs or symptoms of 
urinary tract obstruction without  
hydronephrosis or 
renal dysfunction Signs or symptoms of 
urinary tract obstruction 
with hydronephrosis or 
renal dysfunction Obstruction causing life-threatening 
consequences 
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 64 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Vulvovaginitis  
(symptoms ) 
(Use in studies evaluating topical 
study agents)  
For other 
vulvovaginitis see 
Infection: Infection 
(any other than HIV 
infection) Symptoms causing no or minimal 
interference with 
usual social & 
functional activities  Symptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities  Symptoms causing 
inability to perform usual 
social & functional 
activities  
 Symptoms causing inability to perform basic 
self-care functions  
Vulvovaginitis  
(clinical exam ) 
(Use in studies evaluating topical study agents)  
For other vulvovaginitis 
see Infection: Infection (any other than HIV infection) Minimal vaginal abnormalities on examination OR Epithelial disruption  < 25% of total surface Moderate vaginal abnormalities on examination OR Epithelial disruption of 25 - 49% total surface Severe vaginal abnormalities on examination OR Epithelial disruption  50 - 75% total surface Vaginal perforation OR Epithelial disruption > 75% total surface 
OCULAR/VISUAL 
Uveitis Asymptomatic but 
detectable on exam Symptomatic anterior uveitis OR Medical intervention indicated Posterior or pan-uveitis OR Operative intervention indicated Disabling visual loss in affected eye(s)  
Visual changes (from baseline) Visual changes causing no or minimal interference with usual 
social & functional 
activities Visual changes causing greater than minimal interference with usual 
social & functional 
activities Visual changes causing inability to perform usual social & functional 
activities Disabling visual loss in 
affected eye(s) 
ENDOCRINE/METABOLIC 
Abnormal fat accumulation (e.g., back of neck, breasts, abdomen) Detectable by study participant (or by caregiver for young children and disabled adults) Detectable on physical exam by health care provider Disfiguring OR Obvious changes on casual visual inspection NA 
Diabetes mellitus NA New onset without need 
to initiate medication 
OR Modification of 
current medications to regain glucose control New onset with initiation of medication indicated 
OR Diabetes uncontrolled 
despite treatment modification Life-threatening consequences (e.g., 
ketoacidosis, 
hyperosmolar non-ketotic coma)  
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 65 of 70                                                                                   Version: January 30, 2014 
 PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults) Detectable on physical 
exam by health care provider Disfiguring OR Obvious on casual visual inspection NA 
Hyperthyroidism  Asymptomatic 
 Symptomatic causing greater than minimal interference with usual social & functional activities OR Thyroid suppression therapy indicated Symptoms causing inability to perform usual social & functional activities OR Uncontrolled despite treatment modification  Life-threatening consequences (e.g., thyroid storm) 
Children : Activities that are age and culturally appropriate (e.g., so cial interactions, play acti vities, learning tasks, etc.).  
Hypothyroidism Asymptomatic Symptomatic causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Thyroid 
replacement therapy 
indicated Symptoms causing 
inability to perform usual 
social & functional 
activities OR 
Uncontrolled despite 
treatment modification  Life-threatening consequences (e.g., 
myxedema coma) 
Lipoatrophy (e.g., fat loss from the 
face, extremities, 
buttocks) Detectable by study participant (or by 
caregiver for young 
children and disabled 
adults) Detectable on physical 
exam by health care 
provider Disfiguring OR Obvious 
on casual visual 
inspection NA 
Basic Sel f-care Functions – Adult : Activities such as bathing, dressing, toileti ng, transfer/movement, continence, and feeding. 
Basic Self-care Functions – Young Children : Activities that are age and culturally appr opriate (e.g., feeding self with culturally 
appropriate eating implement). 
Usual Social & Functional Activities – Adult: Adaptive tasks and desirable activities, such as going to work, shopping, 
cooking, use of transportation, pursuing a hobby, etc. 
Usual Social & Functional Activities – Young Children : Activities that are age and culturally appropriate (e.g., social 
interactions, play activiti es, learning tasks, etc.). 
 
 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 66 of 70                                                                                   Version: January 30, 2014 
  
 LABORATORY 
PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING  
HEMATOLOGY  Standard International Un its are listed in italics 
Absolute CD4+ count  
– Adult and Pediatric  
> 13 years 
(HIV NEGATIVE  ONLY)  300 – 400/mm3 
300 – 400/µL  200 –  299/mm3 
200 – 299/µL  100 – 199/mm3 
100 – 199/µL  < 100/mm3 
< 100/µL  
Absolute lymphocyte count  
– Adult and Pediatric   
> 13 years 
(HIV NEGATIVE
 ONLY)  600 – 650/mm3 
0.600 x 109 – 
0.650 x 109/L 500 – 599/mm3 
0.500 x 109 –  
0.599 x 109/L 350 – 499/mm3 
0.350 x 109 –   
0.499 x 109/L < 350/mm3 
< 0.350 x 109/L 
Comment:   Values in children ≤ 13 years are not given for the two parameters above because the absolute counts are variable. 
Absolute neutrophil count (ANC)  
Adult and Pediatric,  
> 7 days  1,000 – 1,300/mm3 
1.000 x 109 – 
1.300 x 109/L 750 – 999/mm3 
0.750  x 109 –  
0.999 x 109/L 500 – 749/mm3 
0.500  x 109 –  
0.749 x 109/L   < 500/mm3 
< 0.500 x 109/L 
Infant∗†, 2 – ≤  7 days 1,250 – 1,500/mm3 
1.250  x 109 –  
1.500 x 109/L 1,000 – 1,249/mm3 
1.000 x 109 –  
1.249 x 109/L 750 – 999/mm3 
0.750  x 109 –  
0.999  x 109/L < 750/mm3 
< 0.750 x 109/L 
Infant∗†, ≤1 day 4,000 – 5,000/mm3 
4.000 x 109 –  
5.000 x 109/L 3,000 – 3,999/mm3 
3.000 x 109 –  
3.999 x109/L 1,500 – 2,999/mm3 
1.500 x 109 –  
2.999 x 109/L < 1,500/mm3 
< 1.500 x 109/L 
Comment:  Parameter changed from “Infant, < 1 day” to “Infant, ≤1 day” 
Fibrinogen, decreased 100 – 200 mg/dL 
1.00 – 2.00 g/L 
OR 
0.75 – 0.99 x LLN 75 – 99 mg/dL 0.75 – 0.99 g/L 
OR 0.50 – 0.74 x LLN 50 – 74 mg/dL 0.50 – 0.74 g/L 
OR 0.25 – 0.49 x LLN < 50 mg/dL  
< 0.50 g/L 
OR 
< 0.25 x LLN  
OR  Associated with gross 
bleeding  
∗ Values are for term infants.  Preterm infant s should be assessed using local normal ranges. 
† Use age and sex appropriat e values (e.g., bilirubin). 
 
  
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 67 of 70                                                                                   Version: January 30, 2014 
 LABORATORY 
PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING  
Hemoglobin (Hgb) 
Comment:  The Hgb values in mmol/L have changed because the conversion factor used to convert g/dL to mmol/L has been 
changed from 0.155 to 0.6206 (the most co mmonly used conversion factor).  For grading  Hgb results obtained by an analytic 
method with a conversion factor other than 0.6206, the result must be converted to g/dL using the appropriate conversion factor  
for that lab. 
Adult and Pediatric 
≥ 57 days   
(HIV POSITIVE  ONLY ) 8.5 – 10.0 g/dL 
5.24 – 6.23 mmol/L 
 7.5 – 8.4 g/dL  
4.62–5.23 mmol/L  6.50 – 7.4 g/dL  
4.03–4.61 mmol/L  < 6.5 g/dL 
< 4.03 mmol/L  
Adult and Pediatric  
≥ 57 days  
(HIV NEGATIVE  ONLY)  10.0 – 10.9 g/dL 
6.18 – 6.79 mmol/L  
OR Any decrease  
2.5 – 3.4 g/dL 1.58 – 2.13 mmol/L  9.0 – 9.9 g/dL 5.55 - 6.17 mmol/L  
OR 
Any decrease  
3.5 – 4.4 g/dL 2.14 – 2.78 mmol/L  7.0 – 8.9 g/dL 4.34 - 5.54 mmol/L  
OR 
Any decrease  
≥ 4.5 g/dL 
> 2.79 mmol/L
 < 7.0 g/dL 
< 4.34 mmol/L 
 
Comment:  The decrease is a decrease from baseline 
Infant∗†, 36 – 56 days 
(HIV POSITIVE  OR 
NEGATIVE ) 8.5 – 9.4 g/dL 
5.24 – 5.86 mmol/L 7.0 –  8.4 g/dL 4.31 – 5.23 mmol/L 6.0 – 6.9 g/dL 3.72 – 4.30 mmol/L < 6.00 g/dL < 3.72 mmol/L 
Infant∗†, 22 – 35 days 
(HIV POSITIVE  OR 
NEGATIVE ) 9.5 – 10.5 g/dL 5.87 - 6.54 mmol/L 8.0 – 9.4 g/dL 4.93 – 5.86 mmol/L  7.0 – 7.9 g/dL 4.34 – 4.92 mmol/L < 7.00 g/dL < 4.34 mmol/L  
Infant∗†, ≤ 21 days 
(HIV POSITIVE  OR 
NEGATIVE ) 12.0 – 13.0 g/dL 7.42 – 8.09 mmol/L 10.0 – 11.9 g/dL 6.18 – 7.41 mmol/L 9.0 – 9.9 g/dL 5.59- 6.17 mmol/L < 9.0 g/dL < 5.59 mmol/L 
Correction :  Parameter changed from “Infant < 21 days” to “Infant ≤  21 days” 
International Normalized 
Ratio of prothrombin time 
(INR) 1.1 – 1.5 x ULN 1.6 – 2.0 x UL N 2.1 – 3.0 x ULN > 3.0 x ULN 
Methemoglobin 5.0 – 10.0% 10.1 – 15.0% 15.1 – 20.0% > 20.0% 
Prothrombin Time (PT) 1.1 – 1.25 x ULN  1.26 – 1.50 x ULN  1.51 – 3.00 x ULN  > 3.00 x ULN  
Partial Thromboplastin Time (PTT) 1.1 – 1.66 x ULN  1.67 – 2.33 x ULN  2.34 – 3.00 x ULN  > 3.00 x ULN  
Platelets, decreased 100,000 –  
124,999/mm3 
100.000 x 109 – 
124.999 x 109/L 50,000 –  99,999/mm3 
50.000 x 109 – 
99.999 x 109/L 25,000 –  49,999/mm3 
25.000 x 109 – 
49.999 x 109/L < 25,000/mm3 
< 25.000 x 109/L 
WBC, decreased 2,000 – 2,500/mm3 
2.000 x 109 –  
2.500 x 109/L 1,500 – 1,999/mm3 
1.500 x 109 –  
1.999 x 109/L 1,000 – 1,499/mm3 
1.000 x 109 –  
1.499 x 109/L < 1,000/mm3 
< 1.000 x 109/L 
∗ Values are for term infants.  Preterm infant s should be assessed using local normal ranges. 
† Use age and sex appropriat e values (e.g., bilirubin). 
  
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 68 of 70                                                                                   Version: January 30, 2014 
 LABORATORY 
PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING  
CHEMISTRIES  Standard International Un its are listed in italics   
Acidosis NA pH < normal, but ≥ 7.3 pH < 7.3 without life-
threatening 
consequences pH < 7.3 with life-
threatening 
consequences 
Albumin, serum, low 3.0 g/dL – < LLN 
30 g/L – < LLN  2.0 – 2.9 g/dL 20 – 29 g/L  < 2.0 g/dL 
< 20 g/L  NA 
Alkaline Phosphatase 1.25 – 2.5 x ULN† 2.6 – 5.0 x ULN† 5.1 – 10.0 x ULN† > 10.0 x ULN† 
Alkalosis NA pH > normal, but ≤ 7.5 pH > 7.5 without life-
threatening 
consequences pH > 7.5 with life-
threatening 
consequences  
ALT (SGPT) 1.25 – 2.5 x ULN 2.6 – 5. 0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 
AST (SGOT) 1.25 – 2.5 x ULN 2.6 – 5. 0 x ULN 5.1 – 10.0 x ULN > 10.0 x ULN 
Bicarbonate, serum, low 16.0 mEq/L – < LLN 
16.0 mmol/L – < LLN  11.0 – 15.9 mEq/L 
11.0 – 15.9 mmol/L  8.0 – 10.9 mEq/L 8.0 – 10.9 mmol/L  < 8.0 mEq/L < 8.0 mmol/L  
Comment:   Some laboratories will report this value as Bicarbonate (HCO 3) and others as Total Carbon Dioxide (CO 2).  These 
are the same tests; values should be graded according to the ranges for Bicarbonate as listed above. 
Bilirubin (Total) 
Adult and Pediatric > 
14 days 1.1 – 1.5 x ULN 1.6 – 2.5 x UL N 2.6 – 5.0 x ULN > 5.0 x ULN 
Infant∗†, ≤ 14 days 
(non-hemolytic) NA 20.0 – 25.0 mg/dL 
342 – 428 µmol/L 25.1 – 30.0 mg/dL 429 – 513 µmol/L > 30.0 mg/dL > 513.0 µmol/L 
Infant∗†, ≤ 14 days 
(hemolytic) NA NA  20.0 – 25.0 mg/dL 342 – 428 µmol/L > 25.0 mg/dL 
> 428 µmol/L 
Calcium, serum, high 
Adult and Pediatric  ≥ 7 days  10.6  – 11.5 mg/dL 
2.65 – 2.88 mmol/L 11.6  – 12.5 mg/dL 
2.89 – 3.13 mmol/L 12.6  – 13.5 mg/dL 
3.14 – 3.38 mmol/L > 13.5 mg/dL > 3.38 mmol/L 
Infant∗†, < 7 days 11.5 – 12.4 mg/dL 
2.88 – 3.10 mmol/L 12.5 – 12.9 mg/dL 3.11 – 3.23 mmol/L 13.0 – 13.5 mg/dL 
3.245 – 3.38 mmol/L > 13.5 mg/dL > 3.38 mmol/L 
Calcium, serum, low  
Adult and Pediatric  
≥ 7 days   7.8  – 8.4 mg/dL 
1.95 – 2.10 mmol/L 7.0  – 7.7 mg/dL 
1.75 – 1.94 mmol/L  6.1  – 6.9 mg/dL 1.53 – 1.74 mmol/L < 6.1 mg/dL 
< 1.53 mmol/L 
Infant∗†, < 7 days  6.5 – 7.5 mg/dL 
1.63 – 1.88 mmol/L 6.0 – 6.4 mg/dL 
1.50 – 1.62 mmol/L 5.50 – 5.90 mg/dL 1.38 – 1.51 mmol/L < 5.50 mg/dL 
< 1.38 mmol/L 
Comment:   Do not adjust Calcium, serum, low or Calcium, serum, high for albumin 
∗ Values are for term infants.  Preterm infant s should be assessed using local normal ranges. 
† Use age and sex appropriat e values (e.g., bilirubin). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 69 of 70                                                                                   Version: January 30, 2014 
 LABORATORY 
PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Cardiac troponin I (cTnI) NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as defined by the manufacturer 
Adult ≥ 18 years  200 – 239 mg/dL 5.18 – 6.19 mmol/L 240 – 300 mg/dL 6.20 – 7.77 mmol/L  > 300 mg/dL > 7.77 mmol/L NA 
Pediatric < 18 years 170 – 199 mg/dL 4.40 – 5.15 mmol/L  200 – 300 mg/dL 5.16 – 7.77 mmol/L  > 300 mg/dL > 7.77 mmol/L  NA 
Creatine Kinase 3.0 – 5.9 x ULN† 6.0 – 9.9 x ULN† 10.0 – 19.9 x ULN† ≥ 20.0 x ULN† 
Creatinine 1.1 – 1.3 x ULN† 1.4 – 1.8 x ULN† 1.9 – 3.4 x ULN† ≥ 3.5 x ULN† 
  
LABORATORY 
PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Glucose, serum, high  
Nonfasting 116 – 160 mg/dL 
6.44 – 8.88 mmol/L 161 – 250 mg/dL 8.89 – 13.88 mmol/L 251 – 500 mg/dL 13.89 – 27.75 mmol/L > 500 mg/dL > 27.75 mmol/L 
     
Fasting 110 – 125 mg/dL 6.11 – 6.94 mmol/L 126 – 250 mg/dL 6.95 – 13.88 mmol/L 251 – 500 mg/dL 13.89 – 27.75 mmol/L > 500 mg/dL > 27.75 mmol/L  
Adult and Pediatric  ≥ 1 month  55 – 64 mg/dL 3.05 – 3.55 mmol/L  40 – 54 mg/dL 2.22 – 3.06 mmol/L  30 – 39 mg/dL 1.67 – 2.23 mmol/L  < 30 mg/dL < 1.67 mmol/L  
Infant∗†, < 1 month 50 – 54 mg/dL 2.78 – 3.00 mmol/L 40 – 49 mg/dL 2.22 – 2.77 mmol/L 30 – 39 mg/dL 1.67 – 2.21 mmol/L < 30 mg/dL < 1.67 mmol/L 
Lactate ULN - < 2.0 x ULN 
without acidosis ≥ 2.0 x ULN without acidosis Increased lactate with 
pH < 7.3 without life-
threatening consequences  Increased lactate with 
pH < 7.3 with life-
threatening consequences  
Comment:  Added ULN to Grade 1 parameter  
LDL cholesterol (fasting) 
Adult ≥ 18 years  130 – 159 mg/dL 
3.37 – 4.12 mmol/L 160 – 190 mg/dL 4.13 – 4.90 mmol/L ≥ 190 mg/dL 
≥ 4.91 mmol/L NA 
Pediatric > 2 - < 18 
years 110 – 129 mg/dL  
2.85 – 3.34 mmol/L 130 – 189 mg/dL 3.35 – 4.90 mmol/L ≥ 190 mg/dL 
≥ 4.91 mmol/L NA 
Lipase 1.1 – 1.5 x ULN 1.6 – 3.0 x ULN 3.1 – 5.0 x ULN > 5.0 x ULN 
Magnesium, serum, low  1.2  – 1.4 mEq/L 
0.60 – 0.70 mmol/L 0.9 – 1.1 mEq/L 
0.45 – 0.59 mmol/L 0.6 – 0.8 mEq/L 0.30 – 0.44 mmol/L < 0.60 mEq/L 
< 0.30 mmol/L  
∗ Values are for term infants.  Preterm infant s should be assessed using local normal ranges. 
† Use age and sex appropriat e values (e.g., bilirubin). 
 
Sangamo BioSciences, Inc. 
Phase 1 Protocol SB-728-1101  Confidential 
 
Page 70 of 70                                                                                   Version: January 30, 2014 
 LABORATORY 
PARAMETER GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
Pancreatic amylas e 1.1 – 1.5 x ULN  1.6 – 2.0 x ULN  2.1 – 5.0 x ULN  > 5.0 x ULN  
Phosphate, serum, low 
Adult and Pediatric  > 14 years 2.5 mg/dL – < LLN 0.81 mmol/L – < LLN 2.0 – 2.4 mg/dL 0.65 – 0.80 mmol/L 1.0 – 1.9 mg/dL 0.32 – 0.64 mmol/L < 1.00 mg/dL 
< 0.32 mmol/L 
Pediatric 1 year – 14 
years  3.0 – 3.5 mg/dL 
0.97 – 1.13 mmol/L 2.5 – 2.9 mg/dL 
0.81 – 0.96 mmol/L 1.5 – 2.4 mg/dL 0.48 – 0.80 mmol/L < 1.50 mg/dL 
< 0.48 mmol/L 
Pediatric < 1 year 3.5 – 4.5 mg/dL 1.13 – 1.45 mmol/L 2.5 – 3.4 mg/dL 
0.81 – 1.12 mmol/L 1.5 – 2.4 mg/dL 0.48 – 0.80 mmol/L < 1.50 mg/dL 
< 0.48 mmol/L  
Potassium, serum, high 5.6 – 6.0 mEq/L 
5.6 – 6.0 mmol/L 6.1 – 6.5 mEq/L 6.1 – 6.5 mmol/L 6.6 – 7.0 mEq/L 
6.6 – 7.0 mmol/L > 7.0 mEq/L > 7.0 mmol/L 
Potassium, serum, low 3.0 – 3.4 mEq/L 
3.0 – 3.4 mmol/L 2.5 – 2.9 mEq/L 
2.5 – 2.9 mmol/L 2.0 – 2.4 mEq/L 2.0 – 2.4 mmol/L < 2.0 mEq/L 
< 2.0 mmol/L 
Sodium, serum, high 146 – 150 mEq/L 
146 – 150 mmol/L 151 – 154 mEq/L 151 – 154 mmol/L  155 – 159 mEq/L 155 – 159 mmol/L ≥ 160 mEq/L 
≥ 160 mmol/L 
Sodium, serum, low 130 – 135 mEq/L 
130 – 135 mmol/L 125 – 129 mEq/L 
125 – 129 mmol/L 121 – 124 mEq/L 121 – 124 mmol/L ≤ 120 mEq/L 
≤ 120 mmol/L 
Triglycerides (fasting) NA 500 – 750 mg/dL 
5.65 – 8.48 mmol/L 751 – 1,200 mg/dL 
8.49 – 13.56 mmol/L > 1,200 mg/dL > 13.56 mmol/L 
Uric acid  7.5 – 10.0 mg/dL 0.45 – 0.59 mmol/L 10.1 – 12.0 mg/dL 0.60 – 0.71 mmol/L 12.1 – 15.0 mg/dL 
0.72 – 0.89 mmol/L > 15.0 mg/dL > 0.89 mmol/L 
URINALYSIS  Standard International Un its are listed in italics  
Hematuria (microscopic)   6 – 10 RBC/HPF > 10 RBC/HPF  Gross, with or without 
clots OR with RBC 
casts Transfusion indicated  
Proteinuria, random 
collection 1 + 2 – 3 +  4 + NA 
Proteinuria, 24 hour collection 
Adult and Pediatric  
≥ 10 years 200 – 999 mg/24 h 
0.200 – 0.999 g/d  1,000 – 1,999 mg/24 h1.000 – 1.999 g/d  2,000 – 3,500 mg/24 h 2.000 – 3.500 g/d  > 3,500 mg/24 h > 3.500 g/d  
Pediatric > 3 mo -  
< 10 years 201 – 499 mg/m2/24 h
0.201 – 0.499 g/d  500 – 799 mg/m2/24 h
0.500 – 0.799 g/d 800 – 1,000  mg/m2/24 h 
0.800 – 1.000 g/d > 1,000 mg/ m2/24 h 
> 1.000 g/d  
∗ Values are for term infants.  Preterm infant s should be assessed using local normal ranges. 
† Use age and sex appropriate values (e.g., bilirubin). 
 